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Abstract
Mallin, Lainey Jo.M.S., Department of Chemistry, Wright State University, 2015.
Proxy-PET building blocks as a Design Element for Library Synthesis

In exploring radioligands for positron emission tomography (PET) imaging, it is not
unusual to synthesize a library of compounds around some targeting scaffold, screen for
optimal binding to a relevant diagnostic cellular target, remove some portion of
optimized molecule so as to append the requisite reporter group, and then re-evaluate. To
this end, the use of “click labeling” in radiochemistry is proving an increasingly attractive
means of conjugating a 18 F-reporter group, wherein the targeting scaffold bearing a
terminal alkyne is allowed to react with a 2-[18 F]-fluoroethylazide to forge a linkage as a
1,2,3-triazole substituent. Since the triazole linked prosthetic group is a necessary portion
of the eventual PET imaging agent, it was envisioned that building blocks possessing a
“cold” version of the triazole linked fluoroethyl group might be incorporated early in the
synthetic plan as a crucial library design element. The analog so designed and exhibiting
optimal binding would, in a radioactive form, represent the eventual PET imaging agent.
To that end, we have prepared such building blocks from the copper(I) catalyzed click
reaction between sodium azide, 2-fluoroethyl tosylate (or benzyl bromide) and
propargylic alcohol. Conversion of the alcohol building block to the corresponding
aldehyde could be effected using MnO 2 , which was appended to a scaffold of interest
using an aldol condensation. Conversion to the bromomethyl derivative was achieved
with PBr3 in the case of the benzyl surrogate but not the fluoroethyl derivative. The
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usefulness of such building blocks has been demonstrated in the case of synthesizing and
evaluating small libraries around the oxindole and isatin privileged scaffolds. Subsequent
manipulations led to the ultimate target structure, being a benzylidene oxindole bearing a
N-triazole linked moiety. For instance, whereas the bromomethyl triazole can be utilized
for N-alkylations of the aforementioned scaffolds towards targets of importance in
Alzheimer’s disease (such as tau proteins, caspase-3, cdk5, and AChE), the aldehyde can
be employed in aldol reactions. The introduction of such proxy-PET moieties at an early
stage of the library synthesis has an added benefit of avoiding the presence of copper
species in the last step before biological testing.
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INTRODUCTION
The year was 1906 and Auguste D. was losing her mind. Dr. Alois Alzheimer
observed this 51 year old woman who was suffering from progressive memory loss as
well as other neurological disturbances such as unwarranted jealousy towards her
husband and delusions that someone was trying to kill her. Upon Auguste's death, Dr.
Alzheimer studied her brain by using silver staining. He identified two types of senile
plaques, namely neuritic plaques (amyloid-β proteins) and neurofibrillary tangles (tauproteins).1 Dr. Alzheimer presented his findings and clinical characteristics of the disease
at a conference in 1906.2
Alzheimer's disease (AD) is a type of dementia that slowly destroys brain
function and leads to cognitive decline as well as behavioral and psychiatric disorders.
Dementia is an umbrella term which describes any disease that irreversibly damages
nerve cells in the brain resulting in a decline in mental ability severe enough to interfere
with performing the activities associated with daily life. 3 Main pathological features of
the disease include the co-occurrence of plaques and tangles, loss of connections between
neurons, and finally neuronal death and brain shrinkage. 4
Over 100 years has passed since Dr. Alzheimer disclosed his discovery of a new
type of neurodegenerative disease later to be named after its discoverer.1,2,5 Little did Dr.
Alzheimer know or could have suspected that the disease he described would become an
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epidemic in the 21st century. Between 1906, when Alzheimer's disease was first
documented, and 2006, one hundred years later, human life expectancy in the United
States increased from 48.5 years to 78.5 years. 6,7 Considering the fact that the principle
risk factor for Alzheimer's disease is age, 8 the prevalence of this disease has risen
dramatically and will continue to do so as life expectancy continues to increase. At
present, there are no cures, treatments, or drugs that can so much as slow the progression
of Alzheimer's disease, nor are there means of diagnosing malady.
Amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) are the hallmarks
of the AD, however with no approved imaging agent to visualize a diagnostic protein in
vivo, it is very difficult to accurately determine pre-mortem if a patient has AD especially
since the symptoms characteristics of AD are similar to those present in other dementias
associated with aging.9,10 While there are imaging agents used in AD research, such
agents target proteins in the brain which do not necessarily correlate well with the
cognitive decline observed.
Symptoms of Alzheimer's disease include memory impairment, decline in
language skills and decision making, behavioral changes, loss of ability to recognize
family, and ultimately loss of self.11 Such a list of pathological symptoms does come
near to describing the devastation and anguish experienced by the patient and their
family. Ronch said it best when he stated: "but worse, the loss of self happens before the
very eyes of the person whose self is vanishing. The basis of unique personal identity
established over the life span eventually deteriorates."12
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Based on Dr. Alzheimer’s findings and another 80+ years of research on the postmortem brains of people who exhibited symptoms similar to those of Auguste D., two
main hypotheses have been developed concerning the cause of the disease. The first, the
so-called “amyloid cascade hypothesis” was developed in 1992 by Hardy and Higgins, 13
who implicated the Aβ plaques as being the causative agent in AD pathology. 13 The
plaques are the result of the sequential cleavage of the amyloid precursor protein (APP)
by β-secretase and ɣ-secretase enzymes which result in the generation of amyloid protein
fragments of 36 to 43 amino acids in length. Of these monomeric species produced, the
A 42 fragment is the most toxic and most prone to aggregation while A 40 is the most
prevalent.14,15 As illustrated by Figure 1; the enzyme β-secretase cleaves the protein in
the extracellular area and then ɣ-secretase cleaves the protein via intra-membrane
proteolysis resulting in formation of the fragments.15 Another secretase, α-secretase is
also involved in the cleavage of APP, however if α-secretase cleaves the protein then no
toxic fragments will be formed.15 In any event, the monomers (especially A 42 ) then
aggregate to form the Aβ plaques thought to initiate the cascade of events leading to
AD.16 At the time, and until very recently, it was thought that since these plaques were
likely the cause of AD, therapeutic strategies aimed at preventing the formation of and/or
facilitating the clearance of these plaques would at least slow down if not cure the
disease.
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Figure 1: APP cleavage by secretases
Now, after several drugs capable of clearing Aβ plaques have been developed and
studied, we are beginning to suspect that ridding the brain of these plaques may have
little or no effect on the progression of the disease. 17,18 Three out of five drugs that have
been developed (none of which have been approved by FDA) to reduce or clear Aβ
plaques are shown. Flurizan19 (1)and Semagacestat20 (2) reduce Aβ burden via ɣsecretase modulation (Flurizan)21 or complete inhibition (Semagacestat). Phenserine 22
(3) works to modulate Aβ generation by non-competitively inhibiting
acetylcholinesterase.
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Two other drugs not shown, Bapineuzumab 23 and Solanezumab,24 are antibodies that
work by binding to the plaques in the brain and activating phagocytosis. When these
drugs were tested on mice, results were very promising showing that plaques were
cleared and symptoms of the disease disappeared causing the mice to seem as though
they were not diseased anymore.25-27 Unfortunately, all of these drugs described had no
effect on the progression of AD in humans and in some cases caused negative side effects
to the patients.22,

28-31

Also, research has shown that the amount of Aβ plaque in the brain

has no correlation with the degree of cognitive impairment; additionally, plaques can be
present in the brain without that person displaying any symptoms of AD. 17,32,33 Hardy did
state in 1994 that “the amyloid cascade hypothesis is just a skeletal outline/framework
not meant to imply that genetics, APP metabolism, and beta-amyloid neurotoxicity are
the only important topics of research in AD or that amyloid deposition is the only cause
of dementia”.34 He stated that the hypothesis only implied that the disease process would
become more biochemically complex with the onset of the cascade. 34 Perhaps his
statements were meant to warn researchers to not to put all their eggs in one basket and to
continue exploring the complexity of AD; however there is no question that most of the
research and funding for AD over the past 20 years has been aimed at targets
implemented with this hypothesis.
Another hypothesis gaining momentum is known as the tau hypothesis. Since
2004, more attention has been given to this hypothesis which was coined by Trojanowski
in 2005,35-38 and suggests that AD pathology starts with hyperphosphorylation of the tau
protein, which in turn, leads to NFT’s and finally the other pathological characteristics of
the disease.39-41 Along with amyloid plaques, NFT’s were first noticed and described by
5

Dr. Alzheimer in 1906, however the protein involved in forming these tangles was not
identified as hyperphosphorylated tau until 1986. 42 In contrast to amyloid plaques, the
amount of neurofibrillary lesions found in the brain does correlate better with the severity
or progression of the disease.43 Research showing that tau pathology appears in certain
areas of the brain decades before Aβ plaques, as well as before signs of dementia surface;
supports the tau hypothesis.44,55 Increased levels of NFT’s in the brain46,47 and in
cerebrospinal fluid48 are positively correlated to reduced scores on cognitive tests 17,46
whereas appearance of Aβ plaques (as mentioned before) do not necessarily mean a
person will ever develop AD.49
In 2011, the Alzheimer’s Association, the National Institute on Aging, and the
U.S. National Institute of Health jointly issued new criteria and guidelines to diagnose
AD. Diagnosis is now based on three clinical stages; preclinical AD, mild cognitive
impairment, and dementia caused by AD. Preclinical AD doesn't have any detectable
symptoms but there is thought to be changes in biomarker levels, however there is no
definite biomarker tracer as of yet so this stage cannot yet be clinically identified premortem. The second stage of AD is mild cognitive impairment which causes symptoms
in the patient such as some memory loss, however, these symptoms are ones that do not
affect the everyday life of the patient. Dementia caused by AD, the third stage, is where
symptoms do interfere with everyday life and those affected become unable to care for
themselves. When AD is diagnosed, there are only a couple of options for the patient:
they can choose to take no action against the disease or they can take palliative
medications which may have little or no effect on the disease progression.4
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As of 2015, there are five medications that have been approved by the FDA as
palliative treatments for the symptoms caused by AD. These drugs vary in effectiveness
and have shown only marginal benefits when found effective. 50 Four of the drugs are
acetylcholinesterase (AChE) inhibitors and one is an N-methyl-D-aspartate (NMDA)
receptor antagonist.51 AChE inhibitors work by slowing down the process that breaks
down acetylcholine (Ach), a key neurotransmitter. 52 NMDA receptor antagonists work by
regulating the activity of glutamate, an important neurotransmitter that regulates the
calcium uptake necessary for proper brain functioning. 53 However, too much of a good
thing can be bad. Excess glutamate can be released from damaged neuronal cells leading
to overexposure to calcium and expedited cell damage. These drugs can help AD patients
manage their symptoms, however they are not disease specific and do not always work. 51
Other drug options that are being explored are ɣ-secretase inhibitors, β-secretase
inhibitors, and α-secretase inhibitors. ɣ-Secretases are involved with a number of critical
processes within the human body and because of that, this protein must be modulated and
not completely inhibited; a challenge which has significantly limited progress in this
area.54 One idea would be to block the ATP binding site on ɣ-secretase that modulates
APP processing.55,56 Netzer et al.56 and Fraering et al.55 describe how modulating the ATP
binding site can reduce Aβ burden. Nonsteroidal anti-inflammatory drugs (NSAID’s)
which allosterically modulate ɣ-secretase so as to produce more of the less toxic 40
amino acid fragments versus 42 fragments might also be an option. 57,58 A better option
would be a drug that interferes with β-secretase because it is not involved in any other
physiological processes. Human APP transgenic mice that have β-secretase genetically
shut off did not have memory defects that they would have normally exhibited. 59 With β7

secretase shut off it cannot cleave APP thus no toxic monomers will be formed which
means that no plaques will form. Alternatively, α-secretase processes the APP at a point
that prevents the more toxic fragments from being produced, which means up-regulation
of this secretase might be a target for intervention.60 Immune mechanisms to clear
plaques in the brain associated with AD could help also, however as mentioned earlier,
five drugs that do this have already failed, so it does not seem like a very promising
avenue.18 Small molecules that can disrupt aggregation might be a viable option as well. 61
One such small molecule is Alzhemed (4), (shown in neutral form) also known as 3amino-1-propanesulfonic acid or 3-aminopropylsulfonic acid. In vitro studies showed
preferential binding to soluble Athus inhibiting Aβ aggregation. Additionally,
treatment of mice with Alzhemed resulted in reduction of A in the brain.62
Unfortunately, in August of 2007 the FDA deemed the stage 3 clinical trials
inconclusive.63

Non-pharmaceutical treatments such as physical and reminiscence therapy have
also been studied. These therapies do not alter the progression of the disease and in the
few studies on effectiveness of these types of treatments; they did not seem to help the
patient all that much.64 The spice curcumin (5) is often used in Indian food to flavor and
give color. It has been proposed that curcumin may be a risk reducer for developing AD
since it is thought to have neuronal protective properties. 65 Caffeine (6) is another natural
remedy that is thought to guard against AD as well as have restorative effects once
8

symptoms appear. There have been a couple of studies that involve mice predisposed to
develop AD and when given the equivalent of 5 cups of coffee a day (for a human) they
take longer to exhibit AD symptoms. Additionally, when the mice are already exhibiting
symptoms of the disease they show improved brain function after they are given
caffeine.66,67

As alluded to earlier, an imaging agent for Alzheimer’s is desperately needed.
Currently, AD can only be diagnosed post-mortem which is not much help except to give
an official cause of death in some cases when an autopsy of an elderly individual is
conducted. A conclusive imaging agent could not only distinguish between the various
dementias associated with aging to provide for better diagnosis, but it could also help
monitor the progression of patients undergoing treatments as they are developed. 68 Out of
the five Aβ positron emission tomography (PET) imaging agents (vide infra) that have
had human trials, three have been approved by the FDA. All of the imaging agents
developed to date have been based on the structures of highly fluorescent dyes: Congo
Red (7), Chrysamine G (8), and Thioflavin T (9) that are used to detect A plaques and
NFTs in the brain post-mortem.70 Amyvid (10) (a.k.a. Florbentapir) was the first to be
approved by the FDA in 2012, followed by Vizamyl (12) (a.k.a. Flutemetamol) in 2013,
and finally, Neuraceq (11) (a.k.a. Florbetaben) in 2014.69 Amyvid and Neuraceq have
structural similarities to Congo Red and Chrysamine G while Vizamyl is similar to
9

Thioflavin T. Each of these agents has been shown to be effective for the non-invasive
imagingof amyloid plaques in the pre-mortem brain. Despite this progress, in 2012 the
Human Amyloid Imaging Conference suggested that appearance of amyloid plaques in a
person’s brain is not good news but not a sentence for developing Alzheimer’s either. 68

10
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Seven molecules, belonging to three classes of compounds, have recently been
developed as possible tau PET imaging agents. Of this group, [18 F]THK523 (13),
[18 F]THK5105 (14), and [18 F]THK5117 (15) are quinoline derivatives, [18 F]T807 (16)
and [18 F]T808 (17) are pyrimidine derivatives, and [11 C]PBB3 (18) and [18 F]FDDNP (19)
are benzothiazole derivatives.71 [18 F]FDDNP (19) was the first tau imaging agent tested
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in vivo and while it was shown to target tau it also targeted Aβ which is undesirable.72
Additionally, [18 F]THK-523 (13) failed to visualize NFTs clearly73 and [11 C]PBB3 (18) is
tagged with a radioactive carbon which is not favored when it comes to developing a
PET-imaging agent.74 In-vivo human studies of [11 C]PBB3,74 [18 F]T807,75 (16) and
[18 F]THK510576 (14) showed promising results, however, an imaging agent for tau has
yet to be approved by the FDA.

11

If AD continues to progress at its current rate and we do not develop a disease
altering medication, it will be devastating for not only the 13.8 million people projected
to have the disease by 2050 but also their families and the economy. 3 A consensus about
what needs to be done about this epidemic needs to be reached. Broadly speaking, either
multiple drugs with different modes of action, or a single drug that has multiple
functions, will be required for individualized regimens which means we, as a nation, have
a long way to go considering what is currently available.
While the amyloid cascade and tau hypotheses offer insight to the pathology and
possible causes of AD, they do not individually explain the full complexity of AD. In
order to move forward with drug discovery efforts for this multi- factorial disease77 there
is growing consensus that the paradigm of the “one-compound-various targets”78,79 must
be employed. Though the etiology of AD is not completely known, experts do know of
several components that contribute to the disease, including Aβ deposits, tau protein
aggregation, oxidative stress, and a decrease in ACh levels. Other “players” involved in
AD development include, but are not on any terms limited to, Ca 2+ imbalance, excess of
Cu2+/Zn in the brain, impairment of mitochondrial function and apoptotic neuronal
death.80
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Development of drugs such as Bapineuzumab, Phenserine, Flurizan,
Semagacestat, and Solanezumab which help clear A plaques out of the brain (outlined
earlier) and tacrine, donepezil, rivastigmine, and galantamine which inhibit AChE to
increase Ach,79 have not been able to even alter or slow progression of the disease. For a
review of all drugs (failed and approved by FDA) developed for AD prior to 2010 refer to
the article by Sabbagh.81 Noteworthy is the fact that the development of these drugs over
the past decades has been based on the “one target one compound” paradigm which has
been very successful in the past for some diseases. However, with a disease as complex
as AD this paradigm has not been, and will not likely be successful. 80 This disease seems
to be very efficient at finding a window to proceed through when a door is closed in its
path. The complexity of this disease, as well as a century old history of failed single
target drugs, warrants the progression into developing a drug that can target more than
one proposed cause of disease at a time. Most efforts along these lines have been based
upon coupling drugs which inhibit acetycholinestease along with targeting some other
component of the disease. Memoquin (20) is an example of a multitarget lead drug that
has been tested and shown to be effective at targeting multiple factors believed to lead to
Alzheimer’s disease, including AChE inhibition, altering expression and deposition of
A and altering hyperphosphorylation and deposition of tau. 82,83 Recently, a dual
inhibition lead compound was disclosed as being capable of inhibiting Dyrk1A (a major
tau kinase) and formation of A plaques.84,85 Although such multitarget drugs are at an
early stage of development, it is clear that this approach is becoming more widespread.
For a general review covering the paradigm of one-compound-various targets (a.k.a.
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polypharmacology) read the article by Rastelli86 or for a review that specifically relates to
AD read the article by León.80

The Ketcha research group at WSU is exploring the idea of polypharmacology by
designing molecules to inhibit caspase-3 and acetylcholinesterase or caspase-3 and
cyclin-dependent kinase 5 (cdk5). These biological targets have the ability to affect
gamma secretase activating protein (GSAP) and the Golgi apparatus which have been
shown to be involved in the development of Alzheimer’s disease. Greengard showed in
2007 that arylidene oxindoles, specifically IC261 [(E)-3-(2,4,6trimethoxybenzylidene)indolin-2-one] (21), could reduce endogenous Aβ production by
possibly inhibiting casein kinase 1 (CK1). 87 However, N-alkylation, which is known to
nullify activity against kinases, of a similar molecule, BSc3927 (22), still showed Ainhibitory activity therefore showing that CK1 was likely not involved. 88
GSAP was discovered to be capable of affecting Aβ production without affecting
other important biologic pathways such as the Notch signaling pathway which is
important for neuronal cell communication. GSAP interacts with amyloid precursor
protein c-terminal fragment (APP-CTF). This interaction directs gamma secretase to
“cut” APP which in turn results in formation of the toxic A-42 fragment. Since,
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inhibiting GSAP does not directly inhibit gamma secretase which has other biologic
function; it is considered a good target for possible Alzheimer’s disease treatment. 89
Almost 15 years ago was the first time caspase-3 was shown to have a link to the
development of Alzheimer’s disease by causing neuronal cell death via apoptosis;90
however in 2014 Practico linked caspase-3 to GSAP.91 He discovered that GSAP must be
activated by caspase-3 in turn showing that caspase-3 may be a good enzyme target to
lower A plaque formation.91

Cyclin dependent kinase (cdk5) is also a target of interest because of the
implications that it is linked to the phosphorylation of tau protein and GRASP65 which is
involved in the stacking of the Golgi apparatus. 92 Cdk5 has also been implicated in
causing neuronal apoptosis.93 In 1992, it was determined that cdk5 was involved in the
hyperphosphorylation of tau94 but only recently was it also linked to fragmentation of the
Golgi apparatus.92 Furthermore, it is thought Golgi fragmentation can lead to the
development of AD.92,95 With a disease as complex as Alzheimer’s disease nothing can
be ruled out as a possible cause. At WSU interest is focused on using moieties capable of
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lowering Aβ plaque production by inhibiting caspase-3 and/or cdk5 utilizing compounds
designed around the privileged heterocyclic scaffolds of oxindole and isatin.
Privileged scaffolds are useful starting points for drug discovery efforts because
by definition they are capable of binding as ligands to multiple unrelated receptors.
Oxindole (24) and isatin (23) are considered privileged scaffolds96 because of their broad
range of biological activities and the multiple sites for diversification that they offer. In
relation to Alzheimer’s disease it is important to note that an oxindole derivative, 25, has
been shown to have binding affinity for tau protein. 97 Other oxindole derivatives have
been shown to be protein kinase inhibitors98 which have been implicated as being
involved with AD pathology.93 Additionally, compounds containing the isatin privileged
scaffold have been used to inhibit caspase-3, also known as cysteine aspartyl-specific
proteases,91,99-101 which has also been woven into the web of pathology leading to AD.
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Based on the usefulness and success of isatin (23) and oxindole (24) in
pharmaceuticals, linking a radioactive tag to such scaffolds could lead to the next
imaging agent or even a drug for Alzheimer's disease. Since the nitrogen atom of these
heterocycles represents a convenient linkage point through N-alkylation, one might
envisage appending the fluorine tag via a simple fluoroethyl linker (e.g., 26)102,103 or via a
polyethylene glycol spacer as in 27.104,105 Since modulating the lipophilicity of PET
imaging is often a critical factor in terms of cell entry and/or wash out from the brain, the
fluoroethyl group might possibly make the targeting molecule too lipophilic.102 Rapid
wash out from non-specific binding sites is necessary to obtain good resolution in the
PET image.106 Introducing the polyethylene glycol moiety between the molecule and the
fluorine tag decreases lipophilicity, however the size of such a linker might preclude
binding to certain targets.102,104,105 A third option that is becoming rather popular is using
fluorethyl azide to introduce the tag to a molecule charged with a propargylic moiety by
“click” chemistry leading to a triazole based linking moiety such as 28.103, 107-111
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Positron Emission Tomography
Positron emission tomography (PET) is an imaging technique that utilizes
compounds labeled with a positron emitting radioisotope in order to image and measure
biochemical processes in vivo.112-114 Rapid development of PET has occurred since the
1970’s with advances in detector systems, improved computing capabilities, and
advances in radiochemistry.115 Imaging agents that have been developed to date are often
labeled with

11 C

or 18 F. Half-life of the radioisotope is an important characteristic to

consider. At a mere 20.4 min the half-life of a11 C labeled compound requires that a
facility wishing to employ it to have an on-site cyclotron for production. The half-life of
18 F, at

109.7min, is more than 5x longer allowing imaging agents bearing this reporter to

be shipped to distant facilities after production. This quality alone makes

18 F label

more

desirable in most cases.113
The development of safe and selective fluorinating agents has allowed for fluorine
to be incorporated into more organic molecules and thus the use of fluorine in
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pharmaceuticals has increased.116 Even with the increase in incorporating fluorine into
more molecules, introducing radioactive fluorine into a molecule for use with PET
imaging still comes with challenges. 116,117
Radioactive fluorine is produced in two forms: the electrophilic form and the
nucleophilic form. The nuclear reaction

20 Ne(d, α) 18 F produces [18 F]F

2 after

the addition

of fluorine-19 carrier gas to remove the very reactive electrophilic form from the target.
The addition of the carrier gas decreases specific activity and maximum radiochemical
yield because for each reaction there is only a 50% chance that the radioactive
electrophilic flourine will react. This reaction is used only when specific activity is not a
concern. The

18 O(p, n)18 F reaction

is used much more often because it employs an

enriched water target with can be regenerated when the nucleophilic form, [18 F]F- , is
trapped on an exchange resin (commonly K 222 ). This reaction provides the nucleophilic
form of fluorine-18, which has high specific activity, in high yields. 113,114,117
Standard strategy for identifying new potential pharmaceutics involves screening
a library of compounds for binding to target (biomarker) and finding optimal candidates.
Then, if a fluorine group was not already present in the precursor molecule, part of the
molecule would be removed so as to append a fluorine containing prosthetic group. This
standard strategy is inconvenient because the molecule would have to have biological and
physical properties re-evaluated.118 This is where the novel idea of Proxy-PET building
blocks will be very helpful.
The idea of Proxy-PET is focused on creating entire libraries of compounds that
are readily available for screening, as well as being potential imaging agents, by using
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only a few building blocks with cold fluorine incorporated. The building blocks could be
attached to various compounds to create a new library of potential PET imaging agents
before screening the library of compounds for binding to target biomarker. If a molecule
has the desired properties, the

18 F can replace

the “cold” fluorine and no additional

testing would be required because the physical and biological properties will not affected.
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Results and Discussion
The goal of this project was, first and foremost, to develop “cold” versions of
potential diagnostic PET imaging agents for use in Alzheimer’s disease in which the
requisite fluoro “tag” (vide infra) would be appended to the targeting agent via a triazole
prosthetic group. In the event that the triazole linker impeded binding to the anticipated
target (tau), these molecules would be studied for alternate purposes such as imaging
caspases or other targets relevant to AD.
In order to image a biological target with a PET scan, a targeting agent with a
radioactive reporter tag such as 18 F or 11 C must first be administered to the patient
(usually intravenously), the imaging agent should then bind to some target of diagnostic
relevance and the photons emitted upon positron annihilation be detected. The

18 F

isotope has become the radiolabel most commonly used with PET imaging because of its
biologic and physical properties as discussed previously. One might imagine two
scenarios by which a radioactive
the first situation, an

18 F-tag might

18 F-atom might

be incorporated into an imaging agent. In

be substituted in place of a fluorine atom already

present in a targeting agent with a demonstrated affinity for the target of interest.
Alternatively, an

18 F-atom might

be appended to the targeting agent by means of some

prosthetic or linking group which ideally would not impede affinity for the target.
However, since less than 30% of molecules of therapeutic interest contain fluorine in
their structure; appending fluorine to a structure is the most commonly employed

21

stratagem, although this sometimes changes the physical and biological properties of the
composite molecule possibly rendering it inactive.117
As many groups recently have also done as a means of appending the fluorine tag,
we chose to explore the use click of chemistry, specifically, the Cu(I)-catalyzed azidealkyne 1,3-dipolar Huisgen cycloaddition (CuAAC).118 This copper mediated reaction
was first demonstrated by Sharpless and Meldal119,120 to regioselectively produce 1,4disubstituted-1,2,3-triazolesand has become increasingly popular as a means of rapidly
introducing radiolabeled tags for use with PET. Azides and alkynes are essentially inert
to most biological conditions and will only react with each other;119,121 a feature termed
orthogonality. Additionally they are small in size and can easily be introduced into
organic compounds.121,109
In developing an imaging radiotracer by the “click labeling” process, a library of
compounds is normally synthesized around a certain targeting scaffold and screened for
optimal binding to a relevant diagnostic cellular target. Upon identification of an optimal
binding substrate, an alkynyl substituent is introduced at some position deemed noncritical for binding, whereupon the triazole linked

18 F-reporter can

be introduced by a

click process with [18 F]fluoroethyl azide ([18 F]FEA) (vide infra) and the radiolabeled
composite molecule then reassessed for affinity to the target. 118
In order to avoid the possibility that introduction of a radiolabeled prosthetic
group interferes with binding to the ultimate biological target in the normal discovery
paradigm, the so-called Proxy-PET concept was developed at WSU and detailed herein.
This new discovery mode for PET imaging agents takes the prospective view that since
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the commonly employed fluoroethyl triazole appendage must be present in any eventual
imaging agent based upon this prosthetic group, building blocks incorporating “cold”
versions of this requisite feature might be prepared and utilized early on in the discovery
process. With such a cold reporter group present in the initial binding assays it can be
readily appreciated that an optimal targeting agent, once discovered, represents the de
facto PET imaging agent when prepared with an 18 F-reporter.
It is important to consider why the 1,2,3-triazole group would make a good
prosthetic group to append the fluorine tag into a molecule. The 1,2,3-triazole moiety
possesses a moderate dipole character as well as hydrogen bond acceptor capabilities due
to the ring nitrogen atoms, and is stable under in vivo conditions. Additionally, triazoles
are resistant to cleavage hydrolytically or otherwise and are almost impossible to oxidize
or reduce.122 Employing the triazole ring as a linker is expected to be advantageous with
regard to the pharmacological properties of a molecule because of biologically favorable
modifications110 such as altered lipophilicity and polarity123 as well as providing a
surrogate for the amide bond.124
Marik and Sutcliffe were the first to employ the CuAAC reaction to label a
protein with

18 F-fluorine

by coupling 3-azido-propionic acid (29) to the N-terminus of a

protein30 and then ‘clicking’ it with a terminal fluoroalkyne 32 to form the triazole as
seen on the protein labeled 33. This illustrated that the CuAAC reaction was a very fast
and efficient method to radiolabel peptides/proteins with

18 F for

targeted imaging using

PET.107 Furthermore, Hausner used the method developed by Marik and Sutcliffe to label
a protein and illustrated how the introduction of the triazole ring does, in fact, have a
significant impact on the in vivo behavior of a radiotracer by altering the above
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mentioned characteristics.125 The triazole linked

18 F-reporter

33 was compared to two

analogues capped with typical acyl linkers (e.g. 34 and 35)which were introduced to the
protein 30 at the N-terminus via condensation reactions. The fluorinated tag 36 was
introduced via a click reaction as described previously. The 3-labeled proteins were
injected into mice and in vivo characteristics such as concentration in certain organs and
metabolism were studied. This was the first time that a radiotracer that had been
introduced via CuACC was studied in vivo and it was concluded that the “clicked”
radiotracer can be considered comparable to other radiotracers; however there were
noticeable differences in pharmacokinetics between each radiotracer underlining the
importance of investigation of each linking group. 125

34

An alternative method to introducing
attach the

18 F to

36

35
18 F via

the CuAAC reaction would be to

the azide moiety as in the case of [18 F]fluoroethylazide ([18 F]FEA) (37),

and then clicking with an alkyne that had been pre-installed in a protein (e.g. 38). In
2007, Glaser and Aarsted first synthesized [18 F]FEA by nucleophilic fluorination of 2azidoethyl-4-toluenesulfonate (40) with anhydrous no-carrier-added Kryptofix 2.2.2
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K +[18 F]F-.This was done in acetonitrile (ACN) and after 15min the [ 18 F]FEA was isolated
via flow-and-trap process.103 Other groups have developed alternative syntheses of
[18 F]FEA over the years, but all involved some sort of distillation procedure to purify the
product such as flow-and-trap or vacuum trap-to-trap. In 2015, Zhou et al. developed a
method to synthesize and isolate [18 F]FEA without distillation. A series of solid phase
extraction cartridges were used to purify the radioisotopically labeled FEA (that had been
synthesized in the same method as previously described) to increase radiochemical yields
and provide a possible platform to perform the click reaction. 126

The examples cited so far involved reporter groups that were introduced onto a
peptide but there is interest in labeling small drug like molecules. In 2009, Nguyen et al.
developed the first small molecule that was labeled with

18 F via

the CuAAC reaction. The

molecule that Nguyen developed was prepared from an isatin 5-sulfonamide derivative
41 that had been N-alkylated with propargyl bromide and then clicked with [18 F]FEA
(37) in the presence of CuSO 4 and sodium ascorbate to yield 42. This molecule was
found to be an effective caspase-3 specific radiotracer to image tumor apoptosis. 127 This
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discovery was especially important for many reasons. One, it showed that a small
molecule could be labeled with the triazole linker.108 Moreover, the small molecule
entailed a scaffold which was one of the backbones to which we envisioned attaching our
building blocks.

41
42
As stated at the outset, we envisioned synthesizing cold “building blocks” using
click chemistry. The term building block was used because these molecules would
incorporate a non-radioactive FEA moiety into a molecule (via the CuAAC reaction) that
would also contain a linking functionality that would be used to append the “block” onto
other molecules. The development of these building blocks as well as how and why they
were introduced to other molecules will be detailed within this section.
Before a fluorine containing building block could be produced, it was necessary
to develop an efficient synthesis of 2-fluoroethyl tosylate (45). Once in hand, it was
anticipated that it could later be reacted with NaN 3 and a propargyl moiety in a one pot
synthesis to produce the desired triazole containing building blocks.
To this end, 2-fluoroethanol (43) was treated with p-toluenesulfonyl chloride (44)
in the presence of triethylamine in EtOAc to produce 2-fluoroethyl tosylate(45).
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43

45

This method was modified from a preparation described by Shealy in a U.S.
patent.128 The original method called for tosyl chloride (44) to be added to EtOAc chilled
in an ice bath and then 2-fluoroethanol (43) and triethylamine (premixed) were to be
added dropwise over 30min, the reaction stirred in an ice bath for 3h and then put in the
refrigerator overnight. The next day the triethylamine hydrochloride that had formed
would be filtered off and the filtrate diluted with hexane to induce precipitation of the
product. The modified method consisted of adding all the reagents except for the 2fluoroethanol (43), which was then added dropwise over 15 min, after which time the
reaction was stirred at rt for an additional 20 h. The product was then purified via
column chromatography using hexanes:ether (1:1). Due to reoccurring low yields, three
initial samples of this product were combined for characterization and the 1 H and

13 C

NMR as well as GCMS spectra of this composite mixture were obtained.
In the 1 H NMR spectrum of 45 (Figure 2), the multiplet at 7.84-7.80 ppm, labeled
c represents the two H’s on the aromatic ring closest to the SO2 , whereas the multiplet d
at 7.39-7.36 ppm corresponds to the two H’s on the aromatic ring nearest the methyl
group. Both of these peaks are expected to be doublets and one can see they resemble
doublets with a few extra tiny peaks at the base of each peak. The four multiplets labeled
a and b between 4.68 and 4.31 ppm correspond to the four H’s on the ethyl moiety. There
are four multiplets instead of two because of the splitting caused by the fluorine atom.
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The two multiplets labeled a represent the two hydrogens on the carbon adjacent to the
fluorine, while the multiplets labeled b are the hydrogens on the carbon adjacent to the
oxygen. These peaks are expected to be doublets of triplets due to splitting by the fluorine
(doublet) and by neighboring methylene hydrogens (triplet). It can be seen in the
spectrum that the pattern is consistent with doublets of triplets (with a few additional
peaks represented within each triplet). Finally, the singlet, e, at 2.47 ppm integrates to 3H
and represents the H’s of the methyl group.129

Figure 2- 1 H NMR Spectrum of 2-fluoroethyl tosylate (45)
The

13 C

NMR of 45, Figure 3, shows nine peaks when there are only seven

unique carbons. This is because of splitting caused by the ½ spin interaction of the two
carbons closest to the fluorine. The set of peaks labeled a and b are actually doublets and
represent the two CH2 carbons (JC-F=173.5 Hz and JC-F=21.23 Hz respectively). The
peak at 145.1 ppm labeled c represents the quaternary carbon with the same label; it is
furthest downfield because of its proximity to the sulfonyl group. The peak labeled f,
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represents the quaternary carbon adjacent to the methyl group. The peak at 129.9 ppm
labeled d represents two carbons on the aromatic ring closer to the sulfonyl group and the
peak at 127.9 ppm labeled e represents the other two carbons on the ring ortho to the
methyl moiety. Finally, the peak at 21.6 ppm, g, represents the methyl carbon. The peaks
represented match literature values closely. 129

Figure 3- 13 C NMR spectrum of 2-fluoroethyl tosylate (45)
As mentioned earlier, our group could initially only obtain this product in low
yield and thus it was deemed necessary to purchase 2-fluoroethyltosylate (45)
(ChonTech). Although this molecule was relatively expensive to purchase, the 2fluoroethanol (43) starting material was also costly and one would need a 50% yield
every time to make buying the starting material more cost effective than buying the
product. Most of the molecules made using 2-fluoroethyl tosylate (45) in this thesis were
made using the purchased variety versus the synthesized variety. However, since we
initially tried to make 2-fluoroethyl tosylate in 2013, an intern in our lab (John van Vliet)
found an alternative method which provides the 2-fluoroethyl tosylate in 70% yield.130
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To gain experience with performing click reactions, before using the expensive 2fluoroethyltosylate, a known compound 49 was synthesized to test reaction parameters.
The compound was produced by reacting benzyl bromide (46) with sodium azide (47)
and propargyl alcohol (48) in the presence of copper sulfate and sodium ascorbate in, at
first, t BuOH/H2 O as a solvent based on reactions reported by Fokin and Sharpless.119
While these authors used copper sulfate and sodium ascorbate in catalytic amounts of 1
mol % and 5 mol %, respectively, we chose to increase the proportions of these species to
5 mol % and 10 mol % as described by Rivero.131 Although this reaction was successful,
yields at first were not particularly desirable, ranging from 3% to 33.3%. In looking for
ways to improve upon this process, we noted that several groups had success synthesizing
1,2,3-triazoles in the most environmentally friendly solvent, H2 O.132-134 Of the groups that
used H2 O, Kacprzak134 utilized the CuSO 4 *H2 O and sodium ascorbate catalyst system as
described previously, however the other groups employing water used different catalysts
such as Cu/C and Cu(II) acetate.132,133 Unfortunately, in the present work, when the
reaction was attempted using water as the only solvent, the reaction was unsuccessful. A
group in 2007 had performed this same reaction in EtOH/H2 O (1:1) in the presence of
triethylamine (TEA)135 and obtained almost 100% yield. Attempting this reaction under
those conditions led to production of 49 in greater than 90% yield.
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48

49

46
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The structure of 49 was confirmed via 1 H and

13 C

NMR; further evidence was

corroboration with literature melting point and published NMR data.131 Comparison of
experimental data to data of a fully characterized product confirmed 1-benzyl-4(hydroxymethyl)-1H-1,2,3-triazole (49) had been produced.
In the 1 H NMR spectrum of 49 (CDCl3 ) the peak labeled e, at 7.47 ppm, is a
singlet representing the proton on the triazole ring. The multiplet at 7.40-7.31 ppm
represents three (a, b, b,) of the protons on the benzene ring while the multiplet at 7.287.21 ppm represents the remaining two protons (c, c) on the benzene ring. The benzylic
methylene CH2 (d) located between the benzene ring and the triazole ring is represented
by the singlet at 5.48 ppm, while the other singlet at 4.7 ppm represents the other CH2 ,
labeled f, adjacent to the alcohol functional group. The protons at d were located further
down field because of their proximity to the triazole nitrogens. Finally, the hydroxyl
proton labeled g is represented by the broad peak at 4.0 ppm.

Figure 4- 1 H NMR (CDCl3 ) spectrum of 1-benzyl-4-(hydroxymethyl)-1H-1,2,3triazole(49)
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Following is another 1 H NMR spectrum of compound 49. This spectrum was
collected on compound 2 in DMSO-d6 rather than CDCl3 . There are some noticeable
changes when solvents are changed. Most notably the downfield shift of the hydrogen,
labeled g, of the OH group shows the effect of the DMSO-d6 on this molecule. This shift
is due to the OH group interacting with DMSO-d6 which is a strong hydrogen bond
acceptor.

Figure 5- 1 H NMR (DMSO-d6 ) spectrum of 1-benzyl-4-(hydroxymethyl)-1H-1,2,3triazole(49)
The

13 C

NMR of compound 49, Figure 6in CDCl3 , shows the eight peaks

expected. This is because one of the quaternary carbon peaks is not showing up. The
quaternary carbon, labeled g is predicted to appear at 148.2 ppm,131 and can be observed
in this spectrum at 148.9 ppm. The peak at 136.6 ppm represents the quaternary carbon
labeled d. Peaks at 129.2, 128.5, and 128.4 ppm represent c, a, and b, five of the carbons
on the benzene ring. The peak at 123.3 ppm, labeled f, represents the C-H on the triazole
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ring. The placement of the C-H labeled f was determined via a DEPT90

13 C

NMR. The

carbon of the CH2 between the rings is labeled e and appears at 54.2 ppm, whereas the
carbon of the CH2 adjacent to the OH moiety, labeled h, is represented by the peak at
56.1 ppm.

d
f

Figure 6- 13 C NMR (CDCl3 ) spectrum of 1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole
(49)
As mentioned before, this reaction using the inexpensive surrogate benzylic
bromide (46) was first attempted using tBuOH/H2 O as solvent and as before initial
attempts at the click reaction of propargyl alcohol (50) with 2-fluoroethyl tosylate (45)
and sodium azide in the presence of copper sulfate/sodium ascorbate in t BuOH/H2 O were
not encouraging. Upon utilization of the EtOH/H2 O and triethylamine system,131 [1-(2fluoroethyl)-1H-1,2,3-triazol-4-yl]methanol (51) was obtained in good yields [via the
intermediacy of fluoroethyl azide (37)].This keystone building block, while potentially
amenable to Mitsunobu type couplings to substrates, could also be converted to a variety
of building blocks upon subsequent reactions.
33
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The 1 H NMR of compound 51 (CDCl3 ) shows six sets of peaks due to the
splitting caused by the ½ nuclear spin of fluorine.136,137 1 H has a ½ nuclear spin also
which is why the fluorine can cause splitting in the 1 H NMR. The singlet peak labeled c,
at 7.68 ppm, is assigned to the proton on the triazole ring. The multiplet labeled a, at
4.87 ppm corresponds to one of the multiplets arising from the CH2 adjacent to the
fluorine. The other multiplet of this group overlaps one of the multiplets from the
adjacent CH2 group labeled b and centered at 4.71 ppm. The other multiplet b arises from
the CH2 of the ethyl moiety farthest from the fluorine and occurs at 4.62 ppm. The
splitting of both sets of methylene hydrogens is attributed to coupling to the adjacent CH 2
group as well as the fluorine atom ipso or one carbon away. These peaks resemble a
doublet of triplets, however the splitting is not first order so J values cannot be
determined. The singlet at 4.79ppm, labeled d, represents the two hydrogens next to the
hydroxyl group. Finally, the proton of the hydroxyl group is represented by the broad
peak labeled e at 2.98ppm.
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Figure 7- 1 H NMR (CDCl3 ) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methanol(51)
Again, upon switching solvent to DMSO-d6 , changes are observed in the
spectrum. Unlike the case of compound 49, where only minor changes upon switching
solvents were observed, there are significant changes in the spectrum of compound 51 in
DMSO-d6 . Most notable again is the change in the hydrogen labeled e (the hydroxyl
hydrogen); once a singlet at 2.98 ppm in CDCl3 , it now appears as a triplet at 5.22 ppm
(JH-H=5.65 Hz). The chemical shift of the protons labeled d adjacent to the OH group was
also affected: as the singlet at 4.79ppm is now a doublet at 4.52 ppm. The splitting (JHH=5.58

Hz) is caused by the coupling to the adjacent hydrogen labeled e.
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Figure 8- 1 H NMR (DMSO-d6 ) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methanol (51)
The

13 C

NMR (CDCl3 ) of compound 51 shows seven peaks when only five

carbons are present in the molecule. This is due to the two CH2 ’s between the triazole
ring and the fluorine being split each other as well as by the fluorine. The most
downfield peak at 148.1 ppm, labeled d, represents the quaternary carbon in the triazole
ring. The peak labeled c, at 122.8 ppm, is assigned to the other carbon in the triazole ring.
These carbons were assigned based on where they appeared in compound 49. The doublet
at 81.5 ppm, labeled a, is the carbon adjacent to the fluorine (JC-F=177.9 Hz). Greater
splitting is observed with carbon a than at the carbon labeled b, at 50.5 ppm (JC-F =20.5
Hz) because of the proximity to the fluorine. The C adjacent to the OH group is labeled e
and represented in the spectrum at 56.2 ppm.

Figure 9- 13 C NMR (CDCl3 ) spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methanol (51)
Having this primary building block in hand, it was envisaged that 51 might be
convertible to alternative functionalities (e.g., carboxylic acid, aldehyde, halide or
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tosylate) by a series of simple reactions. First though, we again turned to the benzyl
surrogate 49 to test out methods, making sure they would work with a similar more
robust molecule before attempting the reactions on 51.
Oxidation of 49 with MnO 2 led to smooth conversion to the corresponding
aldehyde52while reaction with PBr3 afforded the alkyl bromo derivative 53. Since it was
believed that the carboxylic acid 56 could be prepared from the analogous click reaction
involving propiolic acid (54), an oxidative route to 56 was not explored.

49

57

56
52

53

55

54
Scheme 1
Treatment of compound 49 with MnO2 in dichloroethane (DCE) for 18h at 80ᵒC
yielded the aldehyde 52 in 73% yield. Anticipated uses of such triazole aldehydes include
appending to substrates via aldol type reactions or via reductive amination processes. The
1H

NMR of compound 52 (DMSO-d6 ) confirms that the alcohol derivative 49 was in fact

oxidized to the aldehyde 52 since there is no longer a broad OH peak and there is only
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one CH2 signal represented. The benzene carbons are represented by the multiplet
labeled a (7.39-7.35 ppm), and the CH2 between the benzene ring and the triazole ring is
still near where it was before moving from 5.59 ppm in compound 49 to 5.71 ppm (peak
b) in compound 52. The peak at 10.03 ppm, labeled d, represents the proton that is part
of the aldehyde functional group. Finally, proton c representing the proton on the triazole
ring appears at 9.00 ppm.

Figure 10- 1 H NMR spectrum of 1-benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52)
The

13 C

NMR spectrum also confirms the production of the compound 52.

Carbon h is furthest downfield appearing at 185.4 ppm which is typical of an aldehyde
carbonyl group. The quaternary carbon in the triazole ring is represented at 147.5 ppm
and labeled g. The peak labeled f corresponds to the CH in the triazole ring and is at
135.8 ppm. The carbon labeled g is shifted further downfield because of its proximity to
the aldehyde. The four non-equivalent benzene carbons are represented as follows:129.3
ppm, peak c, 128.8 ppm, peak d, 128.7 ppm, peak a, and 128.6 ppm, peak b. Finally, the
carbon between the two rings, e, appears at 53.7 ppm.
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Figure 11- 13 C NMR spectrum of 1-benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52)
The bromo derivative 53 was produced by adding 49 to PBr3 in DCM. The 1 H
NMR and

13 C

NMR spectra confirm the production of compound 53. The 1 H NMR

spectrum shows the absence of the broad hydroxyl peak, which is the only major
difference from the 1 H NMR spectrum (CDCl3 ) of the starting material.

f
d

Figure 12- 1 H NMR spectrum of 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53)
In the

13 C

NMR spectrum of compound 53 all the peaks remained unchanged

from the starting material 49 except for the carbon h. In the starting material 49, the

39

carbon was next to a hydroxyl group whereas now it is adjacent to bromine. Carbon h is
now represented at 21.5 ppm when before it appeared at 56.1 ppm. However, in this
spectrum peak g (145.0 ppm) representing the quaternary carbon in the triazole ring is
present more clearly.

Figure 13- 13 C NMR spectrum of 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53)
It is interesting to note that while this bromomethyl compound was originally
made as a surrogate to examine the critical reaction process and the functional group
interconversion of an alcohol to a bromo derivative, this group could also be used to
practice the N-alkylation of an isatin to yield a triazole linked potential imaging agent. It
turns out that this triazole moiety had already been put at the N-position of isatin but not
by the same method as employed herein. The other group first N-alkylated with
propargyl bromide and then clicked on the benzyl azide 55 moiety.138 Discussion of how
and why 53 was introduced onto isatin will follow.
The method used to produce compound 49 was again used to produce the acid
derivative 56. The only difference was that propiolic acid 54 was added in place of
propargyl alcohol. The workup was a little different too, in that with compound 56, since
HCl was used to acidify the aqueous layer to extract more product into the organic layer.
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The 1 H NMR of compound 56 confirms that a compound containing a triazole
ring was produced however not necessarily the carboxylic acid. The multiplet labeled a,
b, c represents the protons on the benzene ring. The hydrogen, labeled f, associated with
the carboxylic acid moiety is not represented in this 1 H NMR. If it were to be visible it
would appear at about 11.4 ppm as a broad peak. A broad peak in this region was
detectable but only upon peak enhancement. Based on this data it cannot be confirmed
that the carboxylic acid was produced.

Figure 14- 1 H NMR spectrum of1-benzyl-1H-1,2,3-triazole-4-carboxylic acid (56)
The

13 C

NMR of compound 56 also differs from compound 49 but it does not

definitively confirm the presence of the carboxylic acid functionality. The patterns in
which the peaks appear in this spectrum are different than those of the alcohol derivative
49 however they do not confirm the product was produced. The melting point of the
product 56 was much higher than the alcohol 49 which indicated that the acid had been
produced; however the melting point of the product was lower than the literature melting
point.
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Figure 15- 13 C NMR spectrum of 1-benzyl-1H-1,2,3-triazole-4-carboxylic acid (56)
The carboxylic acid would be potentially useful to cap a peptide as shown in the
example reaction on page 24. However, we did not use the compound in any subsequent
reactions because peptides were not used in this thesis.
After it was determined that the MnO 2 and PBr3 reaction worked well with the
benzyl surrogate, to develop additional building blocks the reactions were attempted with
the desired fluoroethyl derivative 51. Although oxidation with MnO 2 led to smooth
conversion to the corresponding aldehyde 58, reaction with PBr3 failed to efficiently
afford the bromo derivative 59. The carboxylic acid derivative 60 was prepared via
addition of propargylic acid (54) to fluoroethyl azide (37) under the same conditions as
used in the attempted preparation of 51. Compound 60 had NMR data to suggest it had
been created, however the sample was too impure to report and since this was not the
building block we were going to use in the near future the reaction was abandoned and
the product was not further purified.
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The 1 H NMR of the aldehyde derivative 58 provides confirmation of structure.
The peak located at 10.11 ppm, labeled d, represents the H of the aldehyde moiety. A
singlet labeled c, at 8.27 ppm, represents the one proton on the triazole ring. The two
multiplets centered at 4.91 ppm and 4.81 ppm represent the two protons adjacent to the
fluorine labeled a; whereas the multiplet at 4.75 ppm represents the two protons labeled
b. The splitting here is, in the case of the protons labeled a, caused by the neighboring
fluorine and CH2 . These peaks confirm the production of the aldehyde because of the
similarities to the spectrum of the starting material 51 (Figure 7) as well as the peak at
10.11 ppm which is indicative of an aldehyde function group and is not present in the
starting material spectrum.
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Figure 16- 1 H NMR spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde (58)
Additionally, the

13 C

NMR spectrum (Figure 17) confirms the starting material 51

was converted to the aldehyde 58. The peak furthest downfield at 184.8 ppm, labeled e,
is representative of an aldehyde carbonyl group. The peak at 147.9 ppm, labeled d,
corresponds to the quaternary carbon also labeled d. Peak c at 126.5 ppm is due to the CH in the triazole ring; this peak is shifted downfield compared to the starting material 51,
where it appears at 122.8 ppm. The peaks labeled a at 81.5 ppm (midpoint),
corresponding to the C adjacent to the fluorine, appears at the same position as in the
starting material. Finally, the peaks labeled b at 50.9 ppm (midpoint) represent the
carbon on the ethyl moiety adjacent to the triazole ring.
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Figure 17- 13 C NMR spectrum of 1-(2-fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde (58)
An elemental analysis was completed on this molecule 58 and the results
confirmed the C, H, and N percentages were within 0.4% of the calculated value for the
expected structure. Since the alcohol starting material 51 exists as an oil and it was not
possible to obtain an elemental analysis for it; the conclusion that 51 had been produced
based on the results of the elemental analysis on the aldehyde derivative 58.
After many unsuccessful attempts to produce and isolate the bromo derivative 59,
it was envisaged that tosylation of the alcohol derivative 51 could be an alternative route
to producing a building block that would be introduced via N-alkylation. Again it was
elected to test reactions on 49 before attempting them with 51. Upon researching the
topic it was found that the tosylation of benzyl alcohols has been accomplished many
times over the years; employing various methods that seemed relatively simple.139-143
However, after attempting to tosylate benzyl alcohol (as a model study) four times with
no formation of product, it became apparent that tosylation of such species was difficult.
A general method was followed from an article published in 2010 titled “A detailed
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investigation of the aza-Prins reaction”. In this paper, Dobbs et al. added the alcohol 62 to
be tosylated to DCM, cooled the solution to 0ᵒC and then added 4dimethylaminopyridine (DMAP), tosylchloride (44) and triethylamine in portions. The
reaction was held at 0ᵒC until complete as determined via thin layer chromatography
(TLC).142 In the present work, the first attempt consisted of adding all the reactants to a
vial at once and letting it stir at room temp for 4h. The reaction was chilled because of a
procedure from a patent that stated the reactions were successful at 25ᵒC.143 After two
failed attempts, the reaction conditions were modified slightly. Thus, the reaction
mixture was chilled, the TEA was added dropwise over 5 min and then the benzyl alcohol
was added dropwise. Once all the reactants were added the temperature was allowed to
reach rt and stirred for an additional 48 h. Based on TLC examination, the product was
never formed as the Rf of the “product” matched the Rf of the starting material even after
reacting for 48 h. For the final attempt the reaction was kept colder for an extended
period of time which resulted in failure also. Finally, an article was discovered that
supported these negative findings, it was titled “Treatment of Alcohols with Tosyl
Chloride Does Not always Lead to the Formation of Tosylates.”144
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In order to utilize the aldehyde 58, isatin (23) and 5-chloro isatin (64) were
reduced to the corresponding oxindoles 24 and 65, respectively. This was accomplished
using 80% hydrazine hydrate over 4 h while refluxing.

As outlined in the introduction, oxindole and isatin scaffolds were chosen because
of their “privileged”nature.96 Oxindoles have a broad range of biological activities,
including protein kinase inhibitors,98 and possible caspase inhibitor,145 cdk5 inhibitor,146
and casein kinase inhibitor. Isatins have been shown to inhibit caspase-3/7.108
To demonstrate the usefulness of the building blocks produced as a means of
appending a fluoroethyl group to a scaffold of interest, the aldol reaction of 5-chloro-2indolinone (65) and aldehyde 58 was explored; the reaction was effective to yield 67.
Likewise,the aldol reaction between 2-indolinone (24) and aldehyde 53 was also effective
to yield 66. It can readily be seen that N-alkylation of this substrate would yield a new
library of compounds of PET-ready targeting agents.
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The 1 H NMR and

13 C

NMR spectra of 66 and 67 confirm the structures of the

products synthesized. Elemental analyses were completed for both molecules 66 and 67
and the results confirmed the C, H, and N percentages were within 0.4% of the calculated
values for each of the molecules.
Compound 67 exists as a mixture of E and Z isomers which was determined by
the 1 H NMR spectrum. Traditionally, E and Z isomers of benzylidene oxindoles are
determined based on the chemical shifts of the aromatic protons on the benzylidene ring
(H-2ꞌ and H-6ꞌ) as well as the shift of the vinylic proton. 147 Compound 67 is similar to but
not actually a benzylidene oxindole, but due to the lack of a model compound of this
type, we have likened the proton of the triazole ring to the H-2ꞌ proton present in a
benzylidene oxindole. Additionally, the vinylic proton can be used as a reference as to
ascertain which isomer is present as well. The E-isomer has a vinylic proton that is more
deshielded due to the influence of the C-2 carbonyl causing a downfield shift. The H-2
and H-6 protons (ortho-benzylidene protons) are affected by the C-2 carbonyl also.
Deshielded protons will be shifted further downfield compared to their shielded
counterparts. In the case of compound 67 there is only one quasi “ortho” proton to
observe. Ortho protons of the E isomer of benzylidene oxindoles are expected to appear
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between 7.45-7.84 ppm, whereas ortho protons in the Z isomer will appear between 7.858.53 ppm. The vinylic proton exhibits chemical shifts as a consequence of shielding also,
however in the E isomer the vinyic proton is deshielded appearing around 7.84 ppm and
in the Z isomer is shielded appearing at about 7.55 ppm.147,148
In the 1 H NMR of 67 the peak furthest downfield at 10.8 ppm, labeled h,
represents the proton on the nitrogen. It is shown as two singlets because of the presence
of both the E/Z isomers. The peaks labeled c, also two singlets, at 9.45 ppm and 8.78
ppm, are assigned to the “ortho” proton on the triazole ring. The peak at 9.45 ppm
indicates there is 30% Z isomer and the peak at 8.78 ppm designates 70% E isomer. The
two doublets labeled d, represent the vinylic proton. The doublet at 9.16 ppm represents
the E isomer 70% and the other doublet 7.99 ppm is assigned to the of the Z isomer 30%.
The singlets at 8.06 ppm and 7.62 ppm, labeled e, are representing the Z and E isomers of
the proton next to the chlorine respectively. Proton f is represented as a doublet of
doublets of doublets at 7.29 ppm and proton g at as an odd looking triplet at 6.88 ppm.
The multiplet at b represents the protons adjacent to the triazole ring whereas the singlet
at 4.82 ppm represents the protons adjacent to the fluorine.
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Figure 18- 1 H NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-5-chloro-1H- indol-2-one (67)
The 1 H NMR of compound 66 indicates that only one isomer is present, unlike
compound 67 which was 70:30 E/Z. The singlet at 10.73 ppm represents the proton on
the nitrogen. The singlet at 9.44 ppm, labeled c, is indicative of the hydrogen of the
triazole ring. The final singlet, d, appearing at 7.90 ppm, is associated with the vinylic
proton. Based on comparison with the vinylic and C-2 proton in the 1 H NMR of
compound 67 it can be determined that this compound (66) exists as the Z isomer
(100%). Proton e, is represented by the doublet (JH-H=7.51 Hz) at 7.80 ppm; the splitting
is caused by the adjacent proton f. Proton f, a triplet at 7.23 ppm (J=7.61 Hz) and is split
by two neighboring hydrogens (e and g) both ortho. Proton g is also a triplet split by two
neighboring hydrogens; the peak appears at 6.99 (J=7.52 Hz). The doublet at 6.87 ppm
represents proton h, which is split by the ortho hydrogen g (J=7.72Hz). The multiplets, a
and b, at 4.94 ppm and 4.81 ppm represent the CH2 adjacent to the triazole ring and the
CH2 adjacent to the fluorine respectively.
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Figure 19- 1 H NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-1H-indol-2-one (66)
The13 C NMR of 67 is shown next, where in peaks were estimated using
nmrdb.org predicting program. The peak labeled h is furthest downfield as it should be
since the carbon it represents is attached to the ketone moiety. The peak labeled l and the
peak labeled m correlate to the ethyl moiety and the peaks appear as they did in the
building block 58. This

13 C

NMR spectrum is not as clear as the

66.
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13 C

NMR of compound

Figure 20- 13 C NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-5-chloro-1H- indol-2-one (67)
The

13 C

NMR of compound 66 resembles the

13 C

NMR of compound 67 with the

carbon attached to the double bond oxygen furthest downfield and the ethyl carbons
furthest upfield. The ethyl moiety is represented more clearly in this spectrum.

Figure 21- 13 C NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-1H-indol-2-one (66)
As suggested previously, N-alkylation of compounds 66 and 67 would yield a
new library of compounds of PET ready targeting agents. The N-2,6-difluorobenzyl
fragment had previously been shown by the Ketcha group to enhance the cell-death
inhibitory properties of benzylidene oxindoles (presumably by inhibiting caspase-3). This
caspase inhibitory fragment was therefore appended onto the C-3 triazolyl oxindole by Nalkylation of 66 with 2,6-difluorobenzyl bromine (68) resulting in 69.
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The 1 H NMR of compound 69 confirms its stucture. Comparision to the 1 H NMR
of the starting material 66 shows that the peak at 10.73 ppm assigned to the proton at the
N-1 position is not present in the product. The singlet furthest downfield at 9.58 ppm,
labeled c, corresponds to the proton on the triazole ring, which appears at 9.44 ppm in the
spectrum of the starting material 66. The second singlet at 7.85 ppm, labeled d, appeared
at 7.90 ppm in the starting material and represents the vinylic proton. The protons of h, f,
g, and e; indicating the aromatic protons of the oxindole backbone, all of which were
represented in the spectrum of 66 also. The additional protons labeled k and j at 6.91
ppm as a multiplet represent the three protons on the aromatic ring that was added.
Additionally, the peak labeled i represents the CH2 between the nitrogen and the
difluorobenzyl group. Finally, the ethyl moiety attached to the triazole ring is
represented as three multiplets between 4.72 ppm and 4.97 ppm.
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Figure 22- 1 H NMR spectrum of3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-1-[(2,6-difluorophenyl)methyl]-1H-indol-2-one (69)
The

13 C

NMR of compound 69 can be compared to the

13 C

NMR of compound 66

to determine if the N-alkylation has occurred. The peak at 36.8 ppm labeled n confirms
the presence of the benzylic carbon. Additionally it is important to note the appearance
of 4 additional peaks in the aromatic region due to the 4 unique carbons on the
difluorobenzyl moiety. Software was used to help assign carbons in the aromatic region
due to the sheer number of carbons (nmrdb.org).

Figure 23- 13 C NMR spectrum of 3-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-1-[(2,6-difluorophenyl)methyl]-1H-indol-2-one (69)
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Although a library of N-triazole linked benzylidene oxindoles reporter groups
were initially envisaged as arising via the N-alkylation of a sublibrary of N-H
benzylidene oxindoles, it was also deemed valuable to initially N-alkylate an isatin with
an appropriate triazole based alkylating agent and then conduct a reductive
deoxygenation/aldol sequence. To that end, the bromo derivative 53 was used to directly
alkylate isatin (23) using KF/alumina (6 equiv) in acetonitrile to afford an N-linked
triazole isatin 70. The use of KF/alumina as a solid-supported base was first introduced in
1979 by Ando et al.149 and the Ketcha group has been using it to N-alkylate isatins since
2011.150,151 The main advantage of employing KF/Alumina as a base for abstraction of
the isatin N-H involves its being easily removed from the reaction mixture by simple
filtration. In this case, possibly due to this basic catalyst, the reaction product was
contaminated with impurities.

23

53
70

First and foremost, molecule 70 was synthesized to demonstrate how the bromo
building block could be used to create a “tertiary building block” of sorts (in anticipation
of reduction and diversification by aldolization). Secondly, this molecule is an isatin
derivative, which is significant because in 2008 Aboagye designed a caspase-3/7
inhibitor, and possible imaging agent, that had the isatin core as a critical part of its
structure.126 Also incorporated as part of its structure was the triazole ring. Additionally,
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Jiang and Hansen99 confirmed that the triazole ring at the N-position enhanced caspase-3
inhibition relative to an N-benzyl substituent, thus demonstrating the value of N-linked
triazole isatins. One of their most potent caspase inhibitors contained a benzyl group
attached to the triazole ring in a disubstituted pattern.100
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Ultimately, the goal was to show that being able to produce this N-alkylated isatin
building block 70, which may not be useful in the development of an imaging agent, may
be very useful in creating a caspase-3 inhibitor.
The 1 H NMR and

13 C

NMR spectra of compound 70 confirm its structure.

Additionally, in this case there exists a literature melting point and NMR for comparison.
In the following 1 H NMR spectrum (Fig. 24) each proton is represented. The multiplet
that is furthest downfield at 7.58-7.56 ppm represents three protons: because of the shift
of this set of peaks, it can be determined they represented three of the four protons on the
isatin portion of the molecule, labeled g, i, and j. The next multiplet at 7.31-7.24 ppm is
integrated as 6H; it is believed that the protons labeled b (x2),c (x2), a, and e are
represented by this group of peaks because the latter are all aromatic protons and thus are
appearing in the appropriate range. The final aromatic proton h, appears as a triplet of
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doublets at 7.11 ppm. The splitting is caused by the protons that are ortho to c (JH-H=7.54
Hz) and the proton that is meta to this proton (JH-H=0.73 Hz). At 5.49 ppm two protons,
labeled f, (located between the triazole ring and the nitrogen on the isatin), are
represented by a singlet. The final peak at 4.99 ppm, labeled d, is also a singlet and is
associated with the two protons that exist between the triazole ring and the benzene ring.

a, b, c, e

Figure 24- 1 H NMR spectrum of 1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H- indole2,3-dione (70)
The

13 C

NMR of this structure 70 also confirms the N-alkylation of the isatin.

The peak furthest downfield at 183.0 ppm, labeled f, is indicative of the ketone carbonyl
carbon, while the peak labeled g, 157.9 ppm represents the carbon of the amide function.
Peak h, at 150.2 ppm is attributed to the quaternary carbon next to the nitrogen in the
isatin moiety. The peak at 142.1 ppm, labeled j represents the quaternary carbon on the
triazole ring. Between peak j and peak a, 142.1-111.5 ppm the positions of most of these
peaks were estimated using the free internet program offered at nmrdb.org. The peak
labeled i, at 54.4 ppm, is the C between the triazole ring and the isatin moiety. Finally,
the peak at 35.4 ppm is the C between the benzene ring and the triazole ring. These two
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peaks appear in the bromo derivative 53 too, which makes it easier to determine which
peaks represent the appropriate carbon atoms.

Figure 25- 13 C NMR spectrum of1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole2,3-dione (70)
Having demonstrated the concept of utilizing a surrogate PET building block (i.e.,
triazole alkylating agent) to produce a new type of building block, it was necessary to
demonstrate the reductive deoxygenation of such N-triazole linked isatins using
hydrazine. In the event, the reduction of 70 to 72 worked very well which suggests that it
will be possible to further derivatize such N-alkylated building blocks at the 3-position
via an aldol condensation, especially in the context of caspase-3 inhibitors.
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The1 H NMR of compound 72 (Fig 26) confirms its structure. When compared to
the 1 H NMR of compound 70, the starting material, two extra peaks are observed in the
proton NMR due to the reduction of the ketone at the C-3 position. The protons labeled k
are represented as two doublets at 10.53 ppm (J=14.04 Hz) and 9.77 ppm (J=13.47 Hz),
each doublet representing one hydrogen. As to why these hydrogens are at such a
downfield ppm is baffling. The software used and even experimental spectra of oxindole
represent these hydrogens as a singlet around 3.5 ppm. Even with this evidence that
contradicts the possibility of these hydrogens being represented in this way it is believed
this is the structure of the product produced. All the other peaks present in the starting
material 1 H NMR spectrum match up with the peaks shown here. Also, GC/MS analysis
confirms the expected molecular mass.
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Figure 26- 1 H NMR spectrum of 1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-2-indolinone
(72)
The

13 C

NMR of this structure 72 fits what might be expected or predicted more

closely. In comparison to the starting material 70 two peaks moved, both upfield. Most
notably the peak that had been at 183.0 ppm (labeled f) is shifted to 109.8 ppm, labeled g:
a good indicator that the product had in fact been reduced. Other peaks were assigned to
carbons based on NMR predicting software.

Figure 27- 13 C NMR Spectrum of 1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-2indolinone (72)
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Given that so much difficulty had been faced earlier when attempting to prepare
the bromo derivative 59, it was decided to first N-alkylate the benzylidene oxindole 73
with3-bromo-1-propyne (75) and then “click” with fluoroethylazide (37). This general
approach had been accomplished by other groups and, in fact, all the groups that append
isatin or oxindole with a triazole first N-alkylate with an alkyne. First, as a model study
(not shown), isatin (23) was N-alkylated with 3-bromo-1-propyne (75) and the resulting
product was then “clicked” with FEA. Evidence that this reaction was successful was
based on the appearance of the characteristic fluoroethyl triazole peaks in the 1 H NMR
appearing as multiplets between 4.5 and 5.0 ppm, as well as the correct mass peak in the
LC/MS spectra, however there was also evidence of slight impurities. This compound
was not isolated, but it provided evidence that the reaction concept would work.

The N-propargyl benzylidene oxindole 76 was added to DMF and stirred at 50ᵒC
for 30min before the copper (II) sulfate pentahydrate and sodium ascorbate were added to
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the mixture and the resulting mixture was stirred for an additional 2 min. Finally, sodium
azideand2-fluoroethyltosylate (45) were added and allowed to react with the N-terminal
alkyne at 80ᵒC for 24 h, yielding 78.
The 1 H NMR spectrum of compound 78 displayed a number of peaks and may
show some impurities. Alternatively, the extra peaks may be due to more than one isomer
or possibly splitting caused by the fluorine. The presence of some product can be
confirmed because of the peaks between 5.5 ppm and 4.0 ppm which relate to the
formation of the triazole ring linker. Clarity and separation of the peaks could be better
but one can see the three sets of triplets and one singlet representative of the fluoroethyl
triazole ring that have been observed in many previous 1 H NMR spectra of the
fluoroethyl triazole building blocks.

Figure 28- 1 H NMR spectrum of 3-[(p-methoxyphenyl)methylidene]-5-chloro-1-{[1-(2fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-one (78)
For the next product, 79, the starting material 74 was synthesized and appended
with the propargyl group 75 by Amanda Lock Boyer and used in present work to perform
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the click reaction as described above. This molecule was chosen since Kuret’s group at
Ohio State University determined that 3-(4-dimethylaminobenzylidene) oxindole (74)
was a good candidate molecule for binding to the tau protein.97 As expressed, one of the
goals of the present research was to develop a PET imaging agent selective for tau.
Results showed that 77 was an effective binder to tau protein, Aβ1-42 , and α-synuclein
filaments. Binding to more than one protein in the brain is not ideal in the sense that tau
selectivity, alone, is desired. Of the molecules that Kuret identified as selective for tau,
none were able to cross the BBB.97 Since Ketcha's research group at WSU had been
working with benzylidene oxindoles in the past for other pharmaceutical purposes, it
seemed natural for this group to further examine and derivatize74 in attempt to make the
molecule more selective for tau over Aβ1-42 . Kuret discovered that an iodo group at the
C-5 position on the benzenoid ring did not affect binding to tau so Knisley, with the
Ketcha group, produced compounds containing a chloro group at the C-5 position as well
as a fluoro group. Both derivatives showed enhanced binding to tau. It was determined
that the chloro group on the benzenoid ring enhanced tau binding the most.152 As a
result, Cox, also with the Ketcha group, put the chloro group at different positions on the
benzenoid ring; discovering the chloro at the C-5 position was best for tau binding. Cox
also studied the effects of extended conjugation at the C-3 site. Finally, Cox showed that
N-alkylation of 74 with a methyl group did not affect binding affinity. This discovery
opened up the option to put a reporter group at the N-position so this molecule could be
used as a PET imaging agent for Alzheimer's Disease.153 Lock, also in Ketcha's group,
attached a fluoroethyl group at the N-position as a reporter group.154 This molecule will
likely have the proper lipophilicity in order to cross the BBB. This finding led to
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exploring how to introduce a reporter group at the N-position while modifying the
lipophilicity. Using click chemistry to introduce a triazole ring to this position would
effectively alter lipophilicity and provide another way to introduce the reporter group.123
The triazole ring would also add a third ring moiety. This has the potential to be
beneficial to increasing this molecule’s specific binding to tau since the molecules that
are known to bind to tau selectively have at least three aromatic ring regions connected
by two rotatable bonds.97
The 1 H NMR spectrum of compound 79 shows another derivative of benzylidene
oxindole being first N-alkylated with propargyl bromide 75 and then clicked with
fluoroethyl azide 37. The doublet at 8.41 ppm (J=7.37 Hz) represents the carbon labeled
e. The splitting is due to the neighboring hydrogen at the ortho position. The singlet and
doublet that integrate to 1H at 7.88 ppm, labeled i, describe the E/Z isomer possibility of
the vinylic hydrogen. The peak at 7.67 ppm represents the protons labeled j and
seemingly appears to be a doublet of doublets which also suggests a mixture of E/Z
isomers. The peak at 7.50 ppm that looks as if it is a triplet, labeled g, is associated with
the proton with the same label and the splitting is due to the two ortho hydrogens f and h.
The multiplet of peaks between 7.25 ppm and 6.92 ppm is in the aromatic region and
represents 3H; which are labeled f, h, and c. The final peak in the aromatic region is a
multiplet at 6.75 ppm which represents the hydrogens labeled k. The peaks between 5.14
and 4.50 ppm are indicative of the formation of the triazole ring and elimination of the
alkyne. Finally, the peak at 3.09 ppm, labeled l, is representative of the six equivalent
hydrogens on the dimethylamino group.
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Figure 29- 1 H NMR spectrum of 3-{[p-(dimethylamino)phenyl]methylidene}-1-{[1-(2fluoroethyl)-1H-1,2,3-triazol-4-yl]methyl}-1H-indol-2-one (79)
In hindsight the compounds 78 and 79 should have been prepared in EtOH/H2 O
as a solvent instead of DMF since EtOH/H2 O is much easier to remove from a product.
The solvent used in the click reactions to produce the primary building blocks 49 and 51
was EtOH/H2 O so it would have made sense to perform the click reaction of 37 to 78 and
79 in the same solvent. Additionally, it would not have mattered if the starting materials
for 78 and 79 were totally soluble in EtOH/H2 O based on evidence that a click reaction
will take place even in the event that all of the starting materials are not soluble.163,164 As
the saying goes, hindsight is 20:20.
The following salts were produced mainly as possible AChE inhibitors. AChE has been
implicated into the complex web that is the development of AD. As mentioned in the
Introduction section four of the five drugs that are available to help with symptoms of
AD are AChE inhibitors. Donepezil hydrochloride (79a) shown below is an FDA
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approved AChE inhibitor which is able to cross the BBB. Recently, indolinone-based
inhibitors of acetylcholinesterase were developed based on the structural resemblance to
Donepezil hydrochloride. Many of the compounds synthesized were superior to
Donepezil hydrochloride, especially the 2-chlorobenzyl derivative 79b.155 Given this
level of AChE inhibitory activity exhibited by these benzylidene oxindoles, it was
decided to create a triazolyl analog, first to examine the efficacy of this fragment towards
AChE but also to possibly create an imaging agent for AChE in the case of a fluoroethyl
derivative. To initiate a program towards these goals, the surrogate building block 49 was
used to create a quaternary nitrogen of a 3-pyridyl substituted oxindole (e.g., 80).

To that end, building block 49 was simply added to a solution of 80 in acetonitrile
and allowed to react for 24 h at 60ᵒC resulting in compound 81.
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The 1 H NMR spectra (DMSO-d6 ) of compound 81 confirms its structure. The
peak at 11.0 ppm, labeled m, is indicative of the proton attached at the N-1 position as
seen in other spectra of compounds with the proton. The doublet at 9.18 ppm labeled f
(JH-H=6.96 Hz) represents the protons on the benzyl ring close to the quaternary carbon.
The splitting is caused by the protons that are ortho, labeled e which are represented at
8.68 ppm as a doublet (3 JH-H=6.82 Hz) also. The vinylic proton is represented at 8.43 ppm
as a singlet. Peak h, at 8.09 ppm is attributed to proton on the triazole ring. The doublet
at 7.92 ppm, labeled c, is due to the proton at the C-4 position of the oxindole backbone,
splitting is caused by the meta proton at the C-6 position. At 7.42-7.33 ppm there is a
multiplet that represents the protons labeled a, j, k, and l. The doublet at 6.88 ppm (JHH=8.38

Hz) represents the proton at the C-6 position. Finally the singlet labeled g at 5.97

ppm and the singlet at 5.65 ppm labeled i represent the hydrogens of the two CH2 groups.
These peaks are represented in the bromo building block 53 also.
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Figure 30- 1 H NMR spectrum of 3-({1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4pyridyl}methylidene)-5-chloro-1H- indol-2-one (81)
The

13 C

NMR of displays peaks labeled m and p which are indicative of the

carbons associated with the CH2 groups of the molecule. The peaks between 149.9 ppm
and 112.1 ppm are in the aromatic region and represent the 17 unique aromatic carbons.
The peak at 166.5 ppm, labeled h, is indicative of the amide carbonyl carbon.
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Figure 31- 13 C NMR spectrum of 3-({1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-4pyridyl}methylidene)-5-chloro-1H- indol-2-one (81)
For eventual comparison purposes, the 5-chloro version of the previously
determined optimal derivative bearing a 2-chlorobenzyl capping group was also
synthesized. Thus, compound 83 was likewise made by reaction of 80 with 2chlorobenzyl chloride (82). Compound 83 incorporates the 2-chlorobenzyl fragment
which is effective for Ache inhibition, however it is also possible that such quaternization
might not adversely affect caspase-3 inhibition and such molecules make serve as a dual
function drug.155

The 1 H NMR spectrum of compound 83 indicated that in fact the product was
formed however impurities may be present. The peak at 11.20 ppm, labeled l, represents
the hydrogen on the nitrogen. The doublet of doublets at 9.24 ppm (JH-H=6.80 Hz)
represents the two equivalent hydrogens on the pyridine ring closest to the nitrogen.
Splitting is due to the hydrogens at the ortho position and the fact that E and Z isomers
are present. The doublets at 8.76 ppm and 8.44 ppm, both labeled e, are associated with
the other two hydrogens on the pyridine ring furthest from the N. These peaks could be
represented as a doublet of doublets at 8.60 ppm, and again splitting is due to the ortho
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hydrogens (JH-H=6.69 Hz) and the presence of the E and Z isomers. The split singlet at
8.18 and 7.73 ppm, labeled d is due to the E and Z isomers also. Each peak represents
0.5H and together represent the vinylic proton d. The multiplet at 7.65-7.21 ppm
represents 6H. Those six hydrogens are all associated with an aromatic ring, they are
labeled a, b, h, k, i, and j. Next, another multiplet labeled c, represents the hydrogen
next to the chlorine on the lower 6 member ring. The tiny peak in the middle is not
counted as a peak (an impurity), the peaks are considered a doublet of doublets, with
splitting indicative of interaction with hydrogens e and d. The final peak at 6.07 ppm,
labeled g, is considered a multiplet because of the uneven splitting (J=13.5 Hz). This
splitting does not match with any other splitting patterned in the molecule. Since the CH2
group is the last moiety to be assigned, this peak is assumed to correspond with those
protons.

Figure 32- 1 H NMR spectrum of 3-({1-[(o-chlorophenyl)methyl]-4pyridyl}methylidene)-1H- indol-2-one (83)
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The

13 C

NMR spectrum of compound 83 has the appropriate number of peaks at

the appropriate chemical shifts to lead to the conclusion that the product was in fact
formed. The carbon labeled g appears furthest downfield at as it should since it is part of
an amide moiety.

Figure 33- 13 C NMR spectrum of 3-({1-[(o-chlorophenyl)methyl]-4pyridyl}methylidene)-1H- indol-2-one (83)
Following the theme of dual function drugs, it was decided to create molecules
containing a fragment demonstrated to lower Aβ such as a 2,4,6- or 3,4,5-trimethoxy
fragment with a fragment possibly capable of acting towards GSAP. To the end, the
known molecule 85 was prepared via an aldol condensation between oxindole 24 and the
trimethoxybenzyaldehyde 84. It was envisioned that once appended at the N-position,
this species would be a potential multitarget drug as well. This is not a novel compound,
but as detailed in the multitarget drug section of the introduction, it is useful for cdk-5
inhibition and it was envisioned that appending a 2,6-difluorobenzyl “fragment” at the Nposition would create a cdk-5 inhibitor as well as a caspase inhibitor.
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The 1 H NMR of compound 85 shows the expected and appropriate peaks. At 10.6
ppm a singlet labeled l, represents the proton bonded to the nitrogen. Another singlet at
8.02 ppm, labeled f, represents the two hydrogens, also labeled f, on the trimethoxy
benzene. The vinylic hydrogen is represented next as a singlet at 7.76 ppm. The doublet
furthest downfield, labeled a, represents the proton closest to the nitrogen on the
oxindole. Splitting of this peak (JH-H=7.37 Hz) is due the hydrogen present at the ortho
position. The triplets of doublets, at 7.20 ppm (JH-H=7.62, 0.95 Hz) and 6.99 ppm (JHH=7.57,

0.86 Hz) represent the protons labeled b and c respectively. The triplet splitting

is caused by ortho protons whereas the doublet splitting is caused by each having a
proton that is meta. The final doublet at 6.85 ppm, labeled d, represents the final proton
on the oxindole. Splitting, once again, is due to the ortho interaction (JH-H=7.60 Hz) with
the neighboring hydrogen. The singlet at 3.85 ppm, labeled g, represents six hydrogens
and is associated with the six equivalent hydrogens of the trimethoxy moiety. The final
singlet at 3.75 ppm, integrated to three protons, represents the other three hydrogens of
the remaining methoxy group, labeled as h.
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Figure 34- 1 H NMR spectrum of 3-[(3,4,5-trimethoxyphenyl)methylidene]-1H- indol-2one (85)
The

13 C

NMR of compound 85 shows 15 peaks as expected. The peak at 167.7

ppm is definitely the carbon labeled n. The peaks from 152.7 ppm and 109.8 ppm were
assigned based on an internet program that predicts the location of each carbon based on
the structure. Additionally a DEPT90 of this product was used to determine which peaks
were C-H peaks. The peaks at 137.8, 129.1, 121.5, 119.8, 110.6, 109.8 ppm were C-H
peaks and assigned accordingly. The peak labeled m at 60.6 ppm, and the peak labeled k
at 56.3 ppm represent the three primary carbons each attached to oxygen.
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Figure 35- 13 C NMR spectrum of 3-[(3,4,5-trimethoxyphenyl)methylidene]-1H- indol-2one (85)
The final molecule synthesized was also envisioned as a possible multitarget drug.
The isatin starting material 86 was reduced to 87 with hydrazine in order to allow for an
aldol reaction with the trimethoxybenzaldehyde 84 resulting in composite compound 88.
The trimethoxy group has been linked to lowering the Aβ burden in the AD brain as
demonstrated by Greengard in 2007 with compound 21which incorporates the same
2,4,6-trimethoxy benzylidene group as used in this molecule. The difluoro moiety was
also used because of results that support its value in creating an effective caspase
inhibitor as demonstrated by Abogye and team in 2008 with compound 42.
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The 1 H NMR of compound 88 provides structural evidence that the product was
in fact produced. The singlet e, at 7.52 ppm represents the vinylic photon. The multiplet
at 7.47-7.37 ppm, represents the proton labeled k. The triplet of doublets at 7.20 ppm,
labeled a, represents the proton at the C-7 position. It is split by the neighboring proton,
b, but also is effected by the fluorine atoms that are in close proximity. The triplet at 7.11
ppm represents the protons at the C-5 and C-6 positions. The multiplet represented at
6.93-6.85 ppm labeled j, d is associated with protons on the difluoro benzyl moiety as
well as the proton at the C-4 position. The singlet at 6.37 ppm represents the two
equivalent protons each on the ring of the trimethyl benzyl group. The singlet at 5.03
ppm labeled i represents the alkyl protons and finally the peaks at 3.87 ppm h and 3.75
ppm f, together represent the 9 protons of the methoxy groups.
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Figure 36- 1 H NMR spectrum of 3-[(2,4,6-trimethoxyphenyl)methylidene]-1-[(2,6difluorophenyl)methyl]-1H- indol-2-one (88)
The original goals of this research were to provide a proof of concept synthetic
basis for the so-called Proxy PET concept developed at WSU. To that end, families of
triazolyl linking building blocks containing either a cold fluoroethyl reporter group as
well as the more easily accessible benzyl substituted surrogate group were prepared and
attached to potential targeting agents based on either the isatin or oxindole scaffolds.
Although conversion of the progenitor alcohol building blocks to the corresponding
tosylate building blocks could not be achieved, N-alkylation of the analogous bromo
building block was demonstrated as well as aldolization of an aldehyde building block.
Additionally, a new class of building blocks were demonstrated wherein a primary
building block was attached to an isatin, whereupon reduction to the corresponding
oxindole creates building block which might be diversified by subsequent aldolization
with aryl aldehydes.
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Experimental
General. Melting points were determined via the use of open capillaries with an Electro
thermal melting point apparatus. The 1 H and

13 C

NMR data were obtained on a Bruker

Avance 300 MHz NMR in either CDCl3 or DMSO-d6 solution. Chemical shifts for proton
NMR are reported in δ (ppm) downfield from tetramethylsilane and

13 C

NMR shifts are

calibrated on the DMSO-d6 resonance at 39.50 ppm or the CDCl3 resonance at 77.16
ppm. Coupling constants (J) are in Hz. The following abbreviations are used to describe
peak patterns where appropriate: s, singlet; d, doublet; dd, double doublet; t, triplet; q,
quartet; dt, doublet of triplet; m, multiplet. GC/MS measurements were performed using
Hewlett-Packard 6890 Series GC with auto injection and mass fragments are reported a
mass per charge, m/z. The GC was coupled with a mass spectrometer with HewlettPackard 5973 mass selective detector/quadrupole system. Flash column (Silica Gel,
Premium Rf, 200-400 mesh, Sorbent Technologies) and thin layer chromatography
reactions were performed on silica gel with indicated solvent systems.
2-Fluoroethyl tosylate (45)
To a 50 mL vial charged with dichloromethane (25 mL) and a magnetic stir bar was
added p-toluenesulfonyl chloride (11.7 mmol, 2.234 g), triethylamine (5.4 mL, 39.025
mmol), and 4-dimethylaminopyridine (0.0639 g, 0.523 mmol) while chilling in an ice
bath for 5 min. 2-Fluoroethanol was then added drop wise over 15 min. After stirring at
rt for 20 h the reaction was vacuum filtered and rinsed with hexanes. The solid was
discarded and the filtrate was evaporated under reduced pressure. The resulting oil was
purified by silica gel column (5:1 petroleum ether: ethyl ether). Pure product
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(GCMS/TLC) was collected as a yellow oil (134 mg, 5.13%); Rf=0.72 (EtOAc): 1 H NMR
(300 MHz, CDCl3 ) δ 7.84-7.80 (m, 2H), 7.39-7.36 (m, 2H), 4.68-4.65 (m, 1H), 4.52-4.49
(m, 1H), 4.34-4.31 (m, 1H), 2.47 (s, 3H);

13 C

NMR (75MHz, CDCl3 ) δ 145.1, 129.9,

127.9, 80.55 (d, J=173.5, 1C), 68.43 (d, J=21.23, 1C), 21.64ppm; GCMS (m/z) 218
(M+1) 91 (100%).
1-Benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole (49)
To a 10 mL vial charged with EtOH/H2 O (1:1v/v, 6 mL) and a magnetic stir bar was
added benzyl bromide (360 µL, 3.03mmol), sodium azide (220 mg, 3.38 mmol),
triethylamine (40 µL, 0.28 mmol), CuSO 4 *5H2 O (78.0 mg, 10mol%), sodium ascorbate
(112.7 mg, 20mol%) and propargyl alcohol (200 µL, 3.44 mmol). The reaction vessel
was capped and heated at 70 ºC for 3.5 h. H2 O (10 mL) was added to the mixture. The
product was extracted from the water layer with EtOAc (3 x 20 mL). The organic layer
was dried using Na2 SO4 , filtered and evaporated under reduced pressure to afford a pure
(LC/MS, TLC) off-white solid (527 mg, 92.3%) after allowed to sit overnight: mp 71-74
ºC (lit.131 mp 76-77 ºC; Rf = 0.26 (EtOAc): 1 H NMR (300 MHz DMSO) δ 8.04 (s, 1H),
7.37 - 7.32 (m, 5H), 5.59 (s, 2H), 5.24 (s, 1H), 4.55 (s, 2H);

13 C

NMR (75 MHz, DMSO)

δ148.9, 136.6, 129.2, 128.5, 128.4, 123.3, 55.5, 53.2ppm; LCMS190 (M+1)
[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methanol (51)
To a 10 mL vial charged with EtOH/H2 O (1:1v/v 6 mL) and a magnetic stir bar was
added 2-fluoroethyl tosylate (500 µL, 2.95 mmol), sodium azide (0.3285 g, 5.05 mmol),
and triethylamine (20 µL, 5 mol%). The reaction vessel was capped and heated at 60ᵒC
for 18 h. Then the remaining reactants of propargyl alcohol (200 µL, 3.43 mmol), copper
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sulfate pentahydrate (79.7 mg, 10 mol%), and sodium ascorbate (0.1145 g, 20 mol%)
were added and the mixture was heated at 60ᵒC for an additional 24 h. After cooling to rt,
H2 O (8 mL) was added to the reaction vial and the reaction was vacuum filtered. The
water layer was extracted with EtOAc (3x 15 mL) and the combined organic layers were
evaporated under reduced pressure to afford pure (GCMS/TLC) product as a tan oil. The
aqueous layer was then saturated with Na2 SO4 and extracted with EtOAc to provide
additional product as a tan oil (0.1585 g, 60.48%): Rf = 0.75 (MeOH) 1 H NMR (300 MHz
CDCl3 ) δ 7.68 (s, 1H), 4.87 (t, J=4.84, J= 75.72, 1H), 4.79 (s, 2H), 4.71 (t, J=4.4, 2H),
4.62 (t, J=4.84, J=75.72, 1H), 2.98 (s, 2H); 13 C NMR (75MHz, CDCl3 ) δ 148.1, 122.8,
81.5 (d, J=177.9, 1C), 56.2, 50.5 (d, J= 20.5, 1C); GCMS (m/z) 145 (M+), 54 (100%).
1-Benzyl-4-(carboxaldehyde)-1H-1,2,3-triazole (52)
To a 20 mL vial charged with DCE (7 mL) and a magnetic stir bar was added 1-benzyl-4(hydroxymethyl)-1H-1,2,3-triazole (49) (190 mg, 1 mmol) and MnO 2 (267 mg, 3 mmol).
The reaction mixture was stirred at 80 ºC for 4 h and vacuum filtered through a pad of
zeolite. The pad was washed with DCE (3x 10 mL) and the filtrate evaporated under
vacuum using rotary evaporation to afford a pure (GC-MS / TLC) off-white solid (136.1
mg, 72.8%): mp 79-82 ºC (lit.13 mp89-90 ºC; Rf = 0.70 (EtOAc): 1 H NMR (300 MHz,
DMSO) δ; 10.03 (s, 1H), 8.98 (s, 1H), 7.39-7.35 (m, 5H), 5.71 (s, 2H);

13 C

NMR (75

MHz CDCl3 ) δ 185.4, 147.5, 135.8, 129.3, 128.8, 128.7, 128.6, 53.7ppm; GC-MS (m/z)
187 (M+) 91 (100).
1-Benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53)

79

To a 10 mL round-bottom flask charged with DCM (10 mL) and a magnetic stir bar was
added 1-benzyl-4-(hydroxymethyl)-1H-1,2,3-triazole (49) (1.006 g, 5.3 mmol) and PBr3
(1.5 mL, 16 mmol). The reaction mixture was stirred at rt for 4 h, quenched with H2 O (2
mL) and extracted with DCM (3 x15 mL). The combined organic layers were dried using
anhydrous Na2 SO 4 , filtered and evaporated under reduced pressure to afford a pure (LCMS/TLC) white solid (1.0216 g, 75.9%): mp 124-126 ºC; Rf = 0.74 (EtOAc): 1 H NMR
(300 MHz CDCl3 );δ 7.51 (s, 1H), 7.42-7.37 (m, 3H), 7.31-7.27 (m, 2H), 5.52 (s, 2H),
4.55 (s, 2H) 13 C NMR (75 MHz CDCl3 ) δ; 144.9, 134.2,129.2, 128.2, 122.7, 54.3,
21.6ppm;LC MS (m/z) 254 (M+1).
1-Benzyl-1H-1,2,3-triazole-4-carboxylic acid (56)
To a vial charged with EtOH/H2 O (1:1v/v, 10 mL) and a magnetic stir bar was added
benzyl bromide (340 µL, 2.82 mmol)and sodium azide (190 mg, 2.90 mmol). The
reaction mixture was allowed to stir at 60 ºC for 14 h, after which time the remaining
reagents CuSO 4 *5H2 O (40.9 mg, 0.15 mmol), sodium ascorbate (59.9 mg, 0.29 mmol)
and propiolic acid (200 µL 3 mmol) were added. The reaction mixture was allowed to stir
at 60 ºC for 24h, after which time H2 O (1 mL) was added to the mixture and allowed to
cool in an ice bath. Aqueous NaOH (10%, 3mL) was added to the mixture and then
vacuum filtered. Concentrated HCl was then added to the filtrate until the mixture
reached pH 2. Product was extracted from the filtrate with EtOAc (3 x15 mL) and the
combined organic layers were dried with anhydrous Na2 SO4 , filtered and evaporated
under reduced pressure to afford a pure (TLC) white solid. (471.8 mg, 80.4%): mp 159162 ºC (lit.11 mp177-179 ºC); Rf = 0.60 (EtOAc): 1 H NMR (300 MHz CDCl3 ); δ 8.57 (s,
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1H), 7.40-7.28 (m, 6H), 5.65 (s, 2H):

13 C

NMR (75 MHz CDCl3 ); δ 136.0, 129.4, 129.3,

129.2, 128.7, 128.5, 128.3, 53.5 (d, J=34.6Hz, 1C)ppm.
1-(2-Fluoroethyl)-1H-1,2,3-triazole-4-carbaldehyde (58)
To a 10mL vial charged with dichloroethane (7 mL) and a magnetic stir bar was added
[1-(2-fluoro-ethyl)-1H-[1,2,3]triazol-4-yl]- methanol (51), (0.1410 g, 0.9719 mmol)and
activated MnO 2 (0.237 g, 2.73 mmol). The reaction vessel was capped and heated at
80°C for 18 h. The reaction mixture was vacuum filtered over zeolite and washed with
DCE (3 x 10 mL). The solvent was evaporated under reduced pressure to afford the pure
off-white solid (0.1177 g, 84.66%): mp 70-72ᵒC; Rf = 0.64 (MeOH); 1 H-NMR
(300MHz, CDCl3 ) δ: 10.11 (s, 1H), 8.27 (s, 1H), 4.91 (m, 1H), 4.77 (m, 3H);

13 C

NMR

(75MHz, CDCl3 ) δ: 184.8, 147.9, 126.5, 81.0 (d, J=173.2, 1C), 50.9 (d, J=20.4, 1C);
GCMS (m/z): 143 (M+), 60 (100%); Anal. Calcd for C 5 H6 FN3 O2 : C, 41.96; H, 4.23; N,
29.36 Found: C, 41.72; H, 4.14; N, 29.00
3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-5-chloro-1H-indol-2-one
(67)
To a 10mL vial charged with EtOH (4 mL) and a magnetic stir bar was added 5-chloro-2oxindole (171.8 mg, 1.0 mmol), piperidine (0.147 equiv, 16 µL), and 1-(2-fluoroethyl)1H-1,2,3-triazole-4-carbaldehyde (58) (121.4 mg, 0.8 mmol). The mixture was allowed
to stir for 3 h at 80ᵒC at which time the temperature was decreased to 60ᵒC for an
additional 2 h. The mixture was then allowed to cool to rt and placed in the freezer
overnight. The mixture was vacuum filtered and rinsed with EtOH (10 mL) affording
afford a pure (LC/MS, TLC ) solid (207.6 mg, 83.8%): Rf =0.43 (EtOAc); mp 264-266
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ºC; 1 H NMR (300 MHz, DMSO-d6 ) δ 10.8 (d, J=36.15, 1H), 9.45, 8.78 (s, 0.25H, 0.75H)
, 9.16, 7.99 (d, J=2.25, 0.75H, 0.25H), 8.06, 7.62 (s, 0.25H, 0.75H), 7.30 (ddd, J=19.22,
8.29, 2.17, 1H), 6.88 (ddd, J=9.64, 8.30, 0.37, 1H), 4.99-4.9 (m, 2H), 4.82 (s, 1H); 13 C
NMR (75MHz, CDCl3 ) δ: 169.4, 142.8, 141.9, 130.9, 129.9, 126.5, 125.8, 125.6, 123.6,
123.2, 111.3, 81.1, 51.3 (d, J=19.26, 1H) ppm; MS (m/z) 293 (M++1). Anal. Calcd for
C13 H10 ClFN 4 O: C, 53.34; H, 3.44; N, 19.14; Found: C, 53.38; H, 3.29; N, 18.92.
3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-1H-indol-2-one (66)
To a 10mL vial charged with EtOH (4 mL) and a magnetic stir bar was added oxindole
(0.152g 1.0mmol), piperidine (0.147 equiv, 20 µL), and 1-(2-Fluoroethyl)-1H-1,2,3triazole-4-carbaldehyde (58) (0.1657 g, 1.2 mmol).

The mixture was allowed to stir for

5h at 70ᵒC. The mixture was then allowed to cool to rt and placed in the freezer
overnight. The mixture was vacuum filtered and rinsed with cold EtOH (10 mL)
affording afford a pure (LC/MS, TLC ) solid (0.2601 g, 88.3%): Rf = 0.59 (EtOAc); mp
236-241ºC; 1 H NMR (300 MHz DMSO-d6 ) δ 10.73 (s, 1H), 9.44 (s, 1H),7.90 (s, 1H),
7.80 (d, J=7.51, 1H), 7.23 (t, J=7.61, 1H), 6.99 (t, J=7.52, 1H), 6.87 (d, J=7.72, 1H), 4.94
(dq, J=6.64, 3.40, 2H), 4.81 (dq, J=6.67, 3.44, 2H); 13 C NMR (75MHz, DMSO- d6 ) δ
167.8, 142.5, 141.3, 129.6, 129.2, 125.9, 124.3, 121.7, 120.7, 110.0, 82.4 (J=171.3),
50.67 (J=24.75) ppm; LC/MS (m/z) 259 (M++1) Anal. Calcd for C 13 H10 FN4O: C, 60.46;
H, 4.29; N, 21.69; Found: C, 60.49; H, 4.29; N, 21.70.
3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4-yl]methylidene}-1-[(2,6difluorophenyl)methyl]-1H-indol-2-one (69)

82

To a rbf charged with acetonitrile (10 mL) and a magnetic stir bar was added
KF/Alumina (745.1 mg, 5.36 mmol), and 3-{[1-(2-Fluoroethyl)-1H-1,2,3-triazol-4yl]methylidene}-1H-indol-2-one (199.7mg, 0.9mmol). The mixture was stirred for 5 min
at rt 2-(Bromomethyl)-1,3-difluorobenzene (293.7mg, 1.6mmol) was added and mixture
was reflux for 18 h in which time all the acetonitrile evaporated but reaction was not lost.
The sample was redissolved in acetonitrile and vacuum filtered and washed with hot
acetone. The filtrate was evaporated under reduced pressure to afford a bright yellow
solid that was purified via recrystallization (EtOH) to yield product as bright yellow
crystals (72.6mg, 24.4%): Rf = 0.68 (EtOAC); mp 196-200ºC; 1 H NMR (300 MHz
CDCl3 ) δ 9.58 (s, 1H), 7.92 (dd, J=46.91, 0.62, 1H), 7.63 (m, 1H), 7.25 (m, 2H), 7.09 (m,
1H), 6.91 (m, 3H), 5.12 (s, 2H), 4.97 (dt, J= 8.74, 4.48, 1H), 4.81 (quintet,J=4.73, 2H),
4.74 (q, J=4.03, 1H); 13 C NMR (75MHz, CDCl3 ) δ165.9, 163.3, 143.0, 141.0, 129.9,
129.2, 124.4, 123.4, 122.2, 119.4, 111.8, 111.4, 108.5, 82.3, 79.9, 50.5, 31.8ppm; LCMS
(m/z) 385.1 (M+1).
1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole-2,3-dione (70)
To a solution of isatin (0.1869 g, 1.3 mmol), in acetonitrile (11 mL) was added 6 equiv of
KF/alumina (1.09 g, 6.7 mmol) and the resulting mixture was stirred at rt for 5 min after
which time 1-benzyl-4-(bromomethyl)-1H-1,2,3-triazole (53) was then added to the
stirred solution and the mixture was refluxed for 24 h. The mixture was then allowed to
cool to rt and the suspended KF/alumina was removed by vacuum filtration. The filtrate
was evaporated under reduced pressure to afford a sticky orange solid. Recrystallization
from EtOH afforded the pure (LC/MS / TLC) product as yellow crystals (0.1472g,
42.08%): mp 133-136ᵒC (lit.138 139-141ᵒC); Rf = 0.57 (EtOAc); 1 H NMR (300 MHz,
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DMSO-d6 ): 7.58-7.56 (m, 3H), 7.31-7.24 (m, 6H), 7.11 (td, J =7.54, J =0.73 1H), 5.49 (s,
2H) 4.99 (s, 2H);

13 C

NMR (75MHz, CDCl3 ) δ: 183.0, 157.9, 150.2, 142.1, 138.6, 134.0,

129.2, 128.9, 128.2, 125.3, 124.0, 122.8, 117.5, 111.5, 54.4, 35.4 ppm; MS (m/z) 318 (M+
+1).
1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-2-indolinone (72)
To a rbf charged with hydrazine hydrate 80% (8 mL) and a magnetic stir bar was added
1-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]-1H-indole-2,3-dione (70) (0.79 mmol, 0.2515
g). The reaction mixture was reflux for 4 h. The reaction mixture was added to beaker in
an ice bath. Aqueous HCl (3M) was added until a pH of 4 was attained and the mixture
was allowed to stand overnight. The mixture was vacuum filtered to afford the pure
(LC/MS, TLC) product as golden crystals (188.8 mg, 78.6%): Rf = 0.61 (EtOAc):
mp190-194ᵒC; 1 H NMR (300 MHz DMSO-d6 ) δ 10.53 (d, J=14.04, 1H), 9.77 (d,
J=13.47, 1H), 8.14 (s, 1H), 7.40 (ddd, J= 7.45, 1.24, 0.61, 1H), 7.38-7.34 (m, 1H), 7.337.30 (m, 2H), 7.26 (dd, J=7.60, 1.91, 2H), 7.19 (ddd, J=7.88, 7.46, 1.29, 1H), 5.54 (s,
2H), 4.99 (s, 2H);

13 C

NMR (75MHz, DMSO- d6 ) δ160.8, 142.9, 139.2, 136.4, 129.2,

128.6, 128.3, 127.3, 125.5, 123.9, 122.5, 121.9, 117.7, 109.8, 53.2, 34.5 ppm; LC/MS
(m/z) 305 (M+ +1)
3-[(p-Methoxyphenyl)methylidene]-5-chloro-1-{[1-(2-fluoroethyl)-1H-1,2,3-triazol4-yl]methyl}-1H-indol-2-one (78)
To a 10mL vial charged with N,N-dimethylformamide (5 mL) and a magnetic stir bar was
added 2-fluoroethyltosylate (1 equiv, 0.0648 g,0.224 mmol), and sodium azide (1.1
equiv, 0.0180 g, 0.25 mmol). The mixture was heated for 30min at 50 ºC. After 30min,
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copper (II) sulfate pentahydrate (9.4 mg, 10 mol%) and sodium ascorbate (12.4 mg, 20
mol%) were added to the mixture turning the solution reddish/brown. The mixture was
stirred for 1-2 min in which time the solution changed back to a clear color. 3-[(pMethoxyphenyl)methylidene]-5-chloro-1-(2-propynyl)-1H- indol-2-one (76) (1 equiv.,
0.0708 g, 0.219 mmol) was added to the mixture and the whole was heated at 80 ºC for
24 h. The reaction was cooled in an ice bath and transferred to a beaker with 30 mL cold
water after which 10% NH4 OH (5 mL) was added to the reaction with stirring. The
reaction mixture was then vacuum filtered and then extracted with DCM (40 mL). The
organic layer was evaporated under reduced pressure to afford the desired product as a
pure (LC/MS, TLC) greenish solid (0.0424 g, 46.9%): mp 159-162ºC; Rf =0.53; 1 H NMR
(300 MHz DMSO-d6 ) δ 8.63-6.97 (m, 9H), 5.11 (s, 2H), 4.53 (dt, J=107.63, 40.98, 4H),
3.85 (d, 3H);

13 C

NMR (75 MHz, DMSO-d6 )δ 167.3, 161.6, 151.5, 142.6, 141.8, 139.5,

135.4, 132.2, 130.7, 128.0, 126.6, 123.9, 122.7, 114.9, 114.4, 113.8, 111.4, 55.9,
35.3ppm; LC/MS (m/z) 413 (M+1).
3-{[p-(Dimethylamino)phenyl]methylidene}-1-{[1-(2-fluoroethyl)-1H-1,2,3-triazol-4yl]methyl}-1H-indol-2-one (79)
To a 10mL vial charged with dimethylformamide (5 mL) and a magnetic stir bar was
added 2-fluoroethyltosylate (1 equiv, 0.0502 g,0.224 mmol), and sodium azide (1.1
equiv, 0.0228 g, 0.25 mmol). The mixture was heated for 30min at 50 ºC. After 30 min,
copper (II) sulfate pentahydrate (8.7 mg, 10 mol%) and sodium ascorbate (12.8 mg, 20
mol%) were added to the mixture turning the solution reddish/brown. The mixture was
stirred for 1-2 min. in which time the solution changed back to a clear color. 3-{[p(Dimethylamino)phenyl]methylidene}-1-(2-propynyl)-1H- indol-2-one (77) (1 equiv.,
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0.1046g, 0.219mmol) was added to the mixture and heated at 80 ºC for 24 h. The
reaction was cooled in an ice bath and transferred to a beaker with 30 mL cold water after
which 10% NH4 OH (5 mL) was added to the reaction with stirring. The reaction mixture
was then extracted with DCM (3x 15 mL). The combined organic layers were evaporated
under reduced pressure to afford product as a red oil (LC/MS, TLC). Recrystallization
(DCM/Hexanes) was attempted and was not successful. The DCM/Hexanes were
evaporated under reduced pressure to obtain the oil once again which was added to two
other samples (LJM-2-83 and LJM-2-85) and was purified via silica gel chromatography
(EtOAc/Hexanes 40:60 and flushed with MeOH), to afford pure product (LC/MS, TLC)
as orange/red crystals (0.1668g, 47.6%): Rf = 0.48 (EtOAc); mp 110-115 ºC; 1 H NMR
(300 MHz DMSO-d6 ) δ 8.41 (d, J=7.37, 1H), 7.93-7.83 (m, 1H), 7.68 (dd, J=7.26, 4.50,
2H), 7.51-7.48(m, 1H), 7.25-6.92(m, 3H), 6.75 (td, J=4.48, 2.63, 2H), 5.14 (d, J= 3.65,
2H), 4.83 (q, J=4.36, 1H), 4.66 (dq, J=10.36, 5.03, 2H), 4.55 (q, J=4.86, 1H), 3.09 (s,
6H)ppm; LC/MS (m/z) 319 (M++1).
3-({1-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]-4-pyridyl}methylidene)-5-chloro-1Hindol-2-one (81)
To a rbf charged with acetonitrile (5 mL) and a magnetic stir bar was added 1-benzyl-4(bromomethyl)-1H-1,2,3-triazole (53) (135.6mg, 0.54mmol), and 3-[(4pyridyl)methylidene]-5-chloro-1H-indol-2-one (80) (101.5mg, 0.43mmol). The reaction
was refluxed for 1 h then transferred to a vial (10 mL) where it was heated for 23 h at
60ᵒC. The solution was allowed to cool to rt then vacuum filtered and washed with
hexane (10 mL) to afford a purple solid which was recrystallized with EtOH/H2 O (1:1
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v/v) . A pure (LC/MS) dark purple solid (0.0810 g, 43.9%) was collected by vacuum
filtration and washed with cold EtOH: mp 248-250ᵒC; 1 H NMR (300 MHz DMSO-d6 ) δ
11.0 (s, 1H), 9.18 (d, J=6.96, 2H), 8.68 (d, J=6.82, 2H), 8.43 (s, 1H), 8.09 (s, 1H), 7.92 (s,
1H), 7.42-7.33 (m, 6H), 6.88 (d, J=8.38, 1H), 5.97 (s, 2H), 5.65 (s, 2H)ppm. LC/MS
(m/z) 430 (M+ +1);

13 C

NMR (75MHz, DMSO- d6 ) δ 166.5, 149.9, 144.9, 141.9, 140.6,

136.0, 134.8, 131.7, 130.8, 129.3, 129.1, 128.8, 128.6, 126.5, 125.8, 125.4, 122.4, 112.1,
55.1, 53.5 ppm; Anal. Calcd for C24 H19 ClFN 5 O+: C, 54.72; H, 4.02; N, 12.83; Found: C,
54.81; H, 3.76; N, 12.83.
3-({1-[(o-Chlorophenyl)methyl]-4-pyridyl}methylidene)-1H-indol-2-one (83)
To a 20mL vial charged with acetonitrile (8 mL) and a magnetic stir bar was added 3-[(4pyridyl)methylidene]-5-chloro-1H-indol-2-one (80) (209.4 mg, 0.9 mmol), and 2chlorobenzyl chloride (160 µL, 1.5 mmol). The mixture was stirred at 60ᵒC for 23 h after
which time the reaction was cooled to rt, vacuum filtered, and washed with hexanes (10
mL). The resulting solid was purified via recrystallization (EtOH:H2 O, 1:1) to afford the
pure product (LC/MS, TLC) as black crystals (211.2 mg, 56.9%):Rf = 0.00 (EtOAC); mp
155-160 ºC;1 H NMR (300 MHz DMSO-d6 ) δ 11.20 (s, 1H), 9.22 (dd, J=20.15, 6.80, 2H),
8.76 (d, J=6.86, 1H), 8.44 (d, J=6.51, 1H), 8.18, 7.73 (s, 0.5H, 0.5H), 7.65-7.21 (m, 6H),
6.95 (m, 1H), 6.07 (d, J=13.46, 2H);13 C NMR (75MHz, DMSO-d6 ) δ146.1, 145.2, 132.2,
131.9, 131.7, 130.8, 130.7, 130.5, 129.2, 128.6, 128.2, 124.0, 123.6, 122.4, 112.7, 112.2,
61.3ppm LCMS (m/z) 383/385 (M+1).
3-[(3,4,5-Trimethoxyphenyl)methylidene]-1H-indol-2-one (85)
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To a 10 mL vial charged with EtOH (5 mL) and a magnetic stir bar was added isatin
(158.1 mg, 1.1 mmol), 3,4,5-trimethoxybenzaldehyde (259.8 mg, 1.3 mmol) and
piperidine (0.147 equiv, 20 µL). The reaction was stirred at 70ᵒC for 6 h, allowed to cool
to rt and then placed in the freezer overnight to crystallize. The product was collected via
vacuum filtration. Pure product (LC/MS, TLC) was obtained as a yellow powder (211.2
mg, 56.9%): Rf =0.56 (EtOAC); mp 194-196 ºC;1 H NMR (300 MHz DMSO-d6 ) δ 10.6 (s,
1H), 8.02 (s, 2H), 7.76 (s, 1H). 7.67 (d, J= 7.37, 1H), 7.20 (td, J=7.62, 0.95, 1H), 6.99
(td, J=7.57, 0.86, 1H), 6.85 (d, J=7.60, 1H), 3.85 (s, 6H), 3.75 (s, 3H);13 C NMR (75MHz,
CDCl3 ) δ 167.7, 152.7, 140.9, 140.2, 137.8, 130.0, 129.1, 125.6, 121.5, 119.8, 110.6,
109.8, 60.6, 56.3ppm; LCMS (m/z) 312 (M+1).
3-[(2,4,6-Trimethoxyphenyl)methylidene]-1-[(2,6-difluorophenyl)methyl]-1H-indol-2-one
(88)

To a 15 mL vial charged with EtOH (5 mL) and a magnetic stir bar was added 1-[(2,6difluorophenyl)methyl]-2-indolinone (87) (250.2 mg, 1 mmol), 2,4,6trimethoxybenzaldehyde (259.8 mg, 1.3 mmol) and piperidine (0.147 equiv, 20 µL). The
reaction was stirred at 70ᵒC for 48 h at which time it was cooled to rt and put in the
freezer for 48 h to crystallize. Product was collected via vacuum filtration.
Recrystallization with EtOH was performed on the solid to obtain the pure product
(GCMS/TLC) as yellow crystals (145 mg, 34.4%). Rf=0.50 (60:40 EtOAc: Hexanes) 1 H
NMR (300 MHz DMSO-d6 ) δ 7.52 (s, 1H), 7.47-7.37 (m, 1H), 7.20 (td, J=7.26, 2.24,
1H), 7.11 (t, J=8.15, 2H), 6.93-6.85 (m, 3H), 6.37 (s, 2H), 5.03 (s, 2H), 3.87 (s, 3H), 3.75
(s, 6H); 13 C NMR (75MHz, DMSO-d6 ) δ 167.5, 163.45-163.04 (m, 1H), 159.8-159.6 (m,
1H), 142.3, 130.9 (t, J=10.61, 1H), 129.1, 128.6, 126.3, 124.1, 122.2, 121.9, 112.4 (d,
88

J=7.53, 1H), 112.1 (d, J=7.57, 1H), 108.2, 105.0, 91.3, 32.2, 19.0; GCMS (m/z) 437.1
(M+1) 406 (100%).
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